ABSTRACT

The present invention relates to the combination therapy of specific antibodies which bind human CSF-IR with specific antibodies which bind human PD-L1.
Fig. 2c

CSF-1 ELISA - Cyno Plasma Batch 1
(10 mg/kg anti-CSF1R mAb 2F11-e7)-Animal1

Time Point
Pre-Dose 2 hr 24 hr 48 hr 72 hr 96 hr 168 hr d15 d22

W-CSF (pg/mL)

16000 14000 12000 10000 8000 6000 4000 2000 0
Fig. 2d

CSF-1 ELISA - Cyno Plasma Batch 1
(100 mg/kg anti-CSF1R hMab 2F11-e7)-Animal 1

Time Point

- Pre-Dose
- 2 hr
- 24 hr
- 48 hr
- 72 hr
- 96 hr
- 168 hr
- d15
- d22

M-CSF (pg/ml)

16000
14000
12000
10000
8000
6000
4000
2000
0
COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-1

[0001] The present invention relates to the combination therapy of specific antibodies which bind human CSF-1R with specific antibodies which bind human PD-1.

BACKGROUND OF THE INVENTION

CSF-1R and CSF-1R Antibodies


[0003] CSF-1R is the receptor for CSF-1 (colony stimulating factor 1, also called M-CSF, macrophage colony-stimulating factor) and mediates the biological effects of this cytokine (Sherr, C. J., et al., Cell 41 (1985) 665-676). The cloning of the colony stimulating factor 1 receptor (CSF-1R) (also called c-fms) was described for the first time in Rousseau, M. E., et al., Nature 325 (1987) 549-552. In that publication, it was shown that CSF-1R had transforming potential dependent on changes in the C-terminal tail of the protein including the loss of the inhibitory tyrosine 999 phosphorylation which binds Cbl and thereby regulates receptor down regulation (Lee, P. S., et al., Embo J. 18 (1999) 3616-3628). Recently a second ligand for CSF-1R termed interleukin-34 (IL-34) was identified (Lin, H., et al., Science 320 (2008) 807-811).


[0006] Further signaling is mediated by the p85 subunit of PI3K and Grb2 connecting to the PI3K/AKT and Ras/MAPK pathways, respectively. These two important signaling pathways can regulate proliferation, survival and apoptosis. Other signaling molecules that bind the phosphorylated intracellular domain of CSF-1R include STAT1, STAT3, PLCγ, and Cbl (Boureute, R. P. and Rohrschneider, L. R., Growth Factors 17 (2000) 155-166).

[0007] CSF-1R signaling has a physiological role in immune responses, in bone remodeling and in the reproductive system. The knockout animals for either CSF-1 (Pollard, J. W., Mol. Reprod. Dev. 46 (1997) 54-61) or CSF-1R (Dai, X. M., et al., Blood 99 (2002) 111-120) have been shown to have osteopetrotic, hematopoietic, tissue macrophage, and reproductive phenotypes consistent with a role for CSF-1R in the respective cell types.


PD-L1 and PD-1 Antibodies


[0010] This model further provides for the discrimination of self from non-self and immune tolerance. Bretscher et al., *Science* 169: 1042-1049 (1970); Bretscher, P. A., *N.P.A. USA* 96: 185-190 (1999); Jenkins et al., *J. Exp. Med.* 165: 302-319 (1987). The primary signal, or antigen specific signal, is transduced through the T-cell receptor (TCR) following recognition of foreign antigen peptide presented in the context of the major histocompatibility-complex (MHC). The second or co-stimulatory signal is delivered to T-cells by co-stimulatory molecules expressed on antigen-presenting cells (APCs), and induce T-cells to promote clonal expansion, cytokine secretion and effector function. Loraschew et al., *Ann. Rev. Immunol.* 14: 233 (1996). In the absence of co-stimulation, T-cells can become refractory to antigen stimulation, do not mount an effective immune response, and further may result in exhaustion or tolerance to foreign antigens.

[0011] The simple two-signal model can be an oversimplification because the strength of the TCR signal actually has a quantitative influence on T-cell activation and differentiation.
The invention comprises the combination therapy of an antibody which binds to human CSF-1R with an antibody which binds to human PD-L1 for use in the treatment of cancer, for use in the prevention or treatment of metastasis, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity.

The invention further comprises the use of antibody which binds to human CSF-1R for the manufacture of a medicament for use in the treatment of cancer, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity, wherein the antibody is administered in combination with an antibody which binds to human PD-L1.

The antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

- a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or
- b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or
- c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or
- d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or
- e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

- a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or
- b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or
- c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or
- d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or
- e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or
- f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or
- g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
- h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
- i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
- j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
- k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or
- l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
- m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
- n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
- o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
- p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

In one embodiment the antibody is for use in the treatment of cancer.

In one embodiment the antibody is for use in the prevention or treatment of metastasis.

In one embodiment the antibody is for use in the treatment of bone loss.

In one embodiment the antibody is for use in the treatment of inflammatory diseases.
In one embodiment the antibody is for use in treating or delaying progression of an immune related disease such as tumor immunity.

In one embodiment the antibody is for use in stimulating an immune response or function, such as T cell activity.

[0041] The invention further comprises antibody which binds to human CSF-1R wherein the antibody is administered in combination with an antibody which binds to human PD-L1 for use in

[0042] i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1 ligand-independent CSF-1R expressing tumor cells;

[0043] ii) the inhibition of cell proliferation of tumors with CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing macrophage infiltrate;

[0044] iii) the inhibition of cell survival (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or

[0045] iv) the inhibition of cell differentiation (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes into macrophages;

[0046] wherein the antibody is administered in combination with an antibody which binds to human PD-L1;

[0047] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0048] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0049] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0050] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0051] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0052] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0053] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0054] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

[0055] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

[0056] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

[0057] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

[0058] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

[0059] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

[0060] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

[0061] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

[0062] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

[0063] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

[0064] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

[0065] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

[0066] m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

[0067] n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

[0068] o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

[0069] p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107;

[0070] The invention further comprised an antibody which binds to human CSF-1R, for use in the treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein the anti-CSF-1R antibody is administered in combination with an antibody which binds to human PD-L1;

[0071] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0072] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0073] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0074] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0075] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0076] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0077] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0078] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or
[0079] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or
[0080] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or
[0081] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or
[0082] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or
[0083] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or
[0084] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
[0085] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
[0086] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
[0087] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
[0088] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or
[0089] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
[0090] a) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
[0091] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
[0092] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
[0093] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:107.

[0094] In one embodiment the antibodies are of human IgG1 subclass or human IgG4 subclass.

[0095] The invention further comprises:

[0096] a) a method for
[0097] i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing tumor cells;
[0098] ii) the inhibition of cell proliferation of tumors with CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing macrophage infiltrate;
[0099] iii) the inhibition of cell survival (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or
[0100] iv) the inhibition of cell differentiation (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes into macrophages;

[0101] wherein an antibody which binds to human CSF-1R, is administered in combination with an antibody which binds to human PD-1,

[0102] or

[0103] B) a method of treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein an antibody which binds to human CSF-1R is administered in combination with an antibody which binds to human PD-1.

[0104] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0105] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or
[0106] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or
[0107] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or
[0108] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or
[0109] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0110] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0111] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:90, or
[0112] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or
[0113] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or
[0114] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or
[0115] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or
[0116] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or
[0117] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
[0118] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
[0119] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
[0120] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or
[0121] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
[0122] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
[0123] m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
[0124] n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
[0125] o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:107.
The term “ligand independent” as used herein refers to a ligand-independent signaling through the extracellular ECD (and does not include the ligand independent signaling mediated by activating point mutations in the intracellular kinase domain). In one embodiment CSF-1R ligand in this context refers a CSF-1R ligand selected from human CSF-1 (SEQ ID NO: 86) and human IL-34 (SEQ ID NO: 87); in one embodiment the CSF-1R ligand is human CSF-1 (SEQ ID NO: 86); in one embodiment the CSF-1R ligand is human IL-34 (SEQ ID NO: 87).

The invention comprises the combination treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand (in one embodiment the CSF-1R ligand is selected from human CSF-1 (SEQ ID NO: 86) and human IL-34 (SEQ ID NO: 87); in one embodiment the CSF-1R ligand is human CSF-1 (SEQ ID NO: 86); in one embodiment the CSF-1R ligand is human IL-34 (SEQ ID NO: 87)) (detectable in serum, urine or tumor biopsies), wherein an antibody which binds to human CSF-1R as described herein is administered in combination with an anti-PD-L1 antibody as described herein. The term “increase” of CSF-1R ligand refers to the overexpression of human CSF-1R ligand (in one embodiment the CSF-1R ligand is selected from human CSF-1 (SEQ ID NO: 86) and human IL-34 (SEQ ID NO: 87); in one embodiment the CSF-1R ligand is human CSF-1 (SEQ ID NO: 86); in one embodiment the CSF-1R ligand is human IL-34 (SEQ ID NO: 87)) (detectable in serum, urine or tumor biopsies), wherein an antibody which binds to human CSF-1R as described herein is administered.

The combination therapies of the antibodies described herein show benefits for patients in need of a CSF-1R targeting therapy. The specific anti-CSF-1R antibodies according to the invention show efficient antiproliferative activity against ligand-independent and ligand-dependent proliferation and are especially useful in the treatment of cancer and metastasis in combination with the specific anti-PD-L1 antibodies described herein.

**DESCRIPTION OF THE FIGURES**

**FIG. 1a-b 1c:** Human Monocytes differentiated into macrophages with coculture of GM-CSF or CSF-1 (100 ng/ml ligand). After 6 days differentiation addition of hMab 2F11-e7. Cell viability was measured at day 7 of antibody treatment in a C1G Viability Assay (CellTiterGlo® Promega). Calculation of % cell viability: RLU signals from treated cells divided by RLU signal from untreated control without antibody, (n=4).

**FIG. 1b:** Human Monocytes differentiated into macrophages with GM-CSF (M1) or M-CSF (M2) for 7 days. Phenotype analyzed by indirect fluorescence analysis-staining with anti CD163-PE, anti CD80-PE or anti IL-6R-DFQ/DQ/PE/Zenon-Alexa647 labeled. The number in each histogram corresponds to mean ratio fluorescence intensity (MFI); calculated ratio between mean fluorescence intensity (MFI) of cells stained with the selected antibody (empty histogram) and of corresponding isotype control (negative control; gray filled histogram) (mean±SD; n=5).

**FIG. 2a-d CSF-1 levels in Cynomolgus monkey after application of different dosages of anti-CSF-1R antibody hMab 2F11-e7.**

**FIG. 3** In the presence of TAMs, T cell expansion induced by activation of CD3 and CD28 was suppressed: TAM were isolated from MC38 tumors and co-cultured at the ratios indicated with CSF-1E-labeled CD8+ T cells in the presence of CD3/CD28 stimulation. T cell proliferation was analyzed after 3 days using bead quantification of CSFElow dividing cells. One representative experiment out of two is depicted as means±SEM of triplicate wells.

**FIG. 4** Anti tumor Efficacy of <mouse CSF1R> antibody/<PD-L1> antibody combination in the MC38 mouse CRC in vivo model (Kaplan-Meier Plot for Progression of tumor volume=700 mm3).

**FIG. 5** Anti tumor Efficacy of <mouse CSF1R> antibody/<PD-L1> antibody combination in the subcutaneous syngeneic CT26 WT colon carcinoma in vivo model (Kaplan-Meier Plot for Progression of tumor volume=700 mm3).

**DETAILED DESCRIPTION OF THE INVENTION**

Many tumors are characterized by a prominent immune cell infiltrate, including macrophages. Initially, the immune cells were thought to be part of a defense mechanism against the tumor, but recent data support the notion that several immune cell populations including macrophages may, in fact, promote tumor progression. Macrophages are characterized by their plasticity. Depending on the cytokine microenvironment, macrophages can exhibit so-called M1 or M2 subtypes. M2 macrophages are engaged in the suppression of tumor immunity. They also play an important role in tissue repair functions such as angiogenesis and tissue remodeling which are coopted by the tumor to support growth. In

[0137] By secreting various cytokines such as colony stimulating factor 1 (CSF-1) and IL-10, tumor cells are able to recruit and shape macrophages into the M2 subtype, whereas cytokines such as granulocyte macrophage colony stimulating factor (GM-CSF), IFN-gamma program macrophages towards the M1 subtype. Using immunohistochemistry, it is possible to distinguish between a macrophage subpopulation co-expressing CD68 and CD163, which is likely to be enriched for M2 Macrophages, and a subset showing the CD68+/MHC+ class II antigen, indicative of M1 phenotype, likely to include M1 macrophages. Cell shape, size, and spatial distribution of CD68 and CD163 positive macrophages is consistent with published hypotheses on a tumor-promoting role of M2 macrophages, for example by their preferential location in tumor intersecting stroma, and vital tumor areas. In contrast, CD68+/MHC class II+ macrophages are ubiquitously found. Their hypothetical role in phagocytosis is reflected by clusters of the CD68+/MHC class II+, but CD163-immunopositive phenotype near apoptotic cells and necrotic tumor areas.

[0138] The subtype and marker expression of different macrophage subpopulations is linked to their functional state. M2 macrophages can support tumorigenesis by:

- [0139] a) enhancing angiogenesis via the secretion of angiogenic factors such as VEGF or FGF;
- [0140] b) supporting metastasis formation via secretion of matrix metalloproteinsases (MMPs), growth factors and migratory factors guiding the tumor cells to the blood stream and setting up the metastatic niche (Wyckoff, J., et al., Cancer Res. 67 (2007) 2649-2656);
- [0141] c) playing a role in building an immunosuppressive milieu by secreting immunosuppressive cytokines such as IL-4, IL-10, IL-1ra and IL-10, which in turn regulate T regulatory cell function. Conversely CD4 positive T cells have been shown to enhance the activity of tumor promoting macrophages in preclinical models (Mantovani, A., et al., Eur. J. Cancer 40 (2004) 1660-1667; DeNardo, D., et al., Cancer Cell 16 (2009) 91-102).


[0143] Recently, a so-called immune signature comprising high numbers of macrophages and CD4 positive T cells, but low numbers of cytotoxic CD8 positive T cells was shown to correlate with reduced overall survival (OS) in breast cancer patients and to represent an independent prognostic factor (DeNardo, D., et al., Cancer Discovery 1 (2011) 54-67).

[0144] Consistent with a role for CSF-1 in driving the protumorigenic function of M2 macrophages, high CSF-1 expression in rare sarcomas or locally aggressive connective tissue tumors, such as pigmented villonodular synovitis (PVNS) and tenosynovial giant cell tumor (TGCT) due in part to a translocation of the CSF-1 gene, leads to the accumulation of monocytes and macrophages expressing the receptor for CSF-1, the colony-stimulating factor 1 receptor (CSF-1R) forming the majority of the tumor mass (West, R. B., et al., Proc. Natl. Acad. Sci. USA 3 (2006) 690-695). These tumors were subsequently used to define a CSF-1 dependent macrophage signature by gene expression profiling. In breast cancer and leiomyosarcoma patient tumors this CSF-1 response gene signature predicts poor prognosis (Espinosa, I., et al., Am. J. Pathol. 6 (2009) 2347-2356; Beck, A., et al., Clin. Cancer Res. 3 (2009) 778-787).

[0145] CSF-1R belongs to the class III subfamily of receptor tyrosine kinases and is encoded by the c-fms proto-oncogene. Binding of CSF-1 or IL-34 induces receptor dimerization, followed by autophosphorylation and activation of downstream signaling cascades. Activation of CSF-1R regulates the survival, proliferation and differentiation of monocytes and macrophages (Xiong, Y., et al., J. Biol. Chem. 286 (2011) 952-960).

[0146] In addition to cells of the monocytic lineage and osteoclasts, which derive from the same hematopoietic precursor as the macrophage, CSF-1R/c-fms has also been found to be expressed by several human epithelial cancers such as ovarian and breast cancer and in leiomyosarcoma and TGCT/ PVNS, albeit at lower expression levels compared to macrophages. As with TGCT/PVNS, elevated levels of CSF-1, the ligand for CSF-1R, in serum as well as ascites of ovarian cancer patients have been correlated with poor prognosis (Scholl, S. et al., Br. J. Cancer 62 (1990) 342-346; Price, F. et al., Am. J. Obstet. Gynecol. 168 (1993) 520-527). Furthermore, a constitutively active mutant form of CSF-1R is able to transform NIH3T3 cells, one of the properties of an oncogene (Chambers, S., Future Oncol 5 (2009) 1429-1440).

[0147] Preclinical models provide validation of CSF-1R as an oncology target. Blockade of CSF-1 as well as CSF-1R activity results in reduced recruitment of TAMs. In a clinical trial, anti-CSF-1R monoclonal antibody resulted in elevated CSF-1 expression in tumor cells leading to enhanced TAM recruitment. Blockade of CSF-1R in combination with paclitaxel resulted in activation of CD8 positive cytotoxic T cells leading to reduced tumor growth and metastatic burden in a spontaneous transgenic breast cancer model (DeNardo, D., et al., Cancer Discovery 1 (2011) 54-67).


[0149] CSF-1R is the receptor for the CSF-1R ligands CSF-1 (macrophage colony stimulating factor, also called M-CSF) (SEQ ID No.: 86) and IL-34 (SEQ ID No.: 87) and mediates the biological effects of these cytokines (Sherr, C. J., et al., Cell 41 (1985) 665-676; Lin, H., et al., Science 320 (2008) 807-811). The cloning of the colony stimulating factor-1 receptor (also called c-fms) was described for the first
time in Roussel, M. F., et al., Nature 325 (1987) 549-552. In that publication, it was shown that CSF-1R had transforming potential dependent on changes in the C-terminal tail of the protein including the loss of the inhibitory tyrosine 969 phosphorylation which binds Cbl and thereby regulates receptor down regulation (Lee, P. S., et al., Embo J. 18 (1999) 3616-3628).

[0150] CSF-1R is a single chain, transmembrane receptor tyrosine kinase (RTK) and a member of the family of immunoglobulin (Ig) motif containing RTKs characterized by 5 repeated Ig-like subdomains D1-D5 in the extracellular domain (ECD) of the receptor (Wang, Z., et al Molecular and Cellular Biology 13 (1993) 5348-5359). The human CSF-1R Extracellular Domain (CSF-1R-ECD) (SEQ ID NO: 64) comprises the respective Ig-like subdomains D1-D5, but is missing the D4 subdomain. The human CSF-1R fragment D1-D3 (SEQ ID NO: 66) comprises the respective subdomains D1-D3. The sequences are listed without the signal peptide MCSCIGIQLL: LIVATAWHPGQ G (SEQ ID NO: 67). The human CSF-1R fragment D4-D3 (SEQ ID NO: 85) comprises the respective subdomains D4-D3.

[0151] Currently two CSF-1R ligands that bind to the extracellular domain of CSF-1R are known. The first one is CSF-1 (colony stimulating factor I, also called M-CSF, macrophage; human CSF-1, SEQ ID NO: 86) and is found extracellularly as a disulfide-linked homodimer (Stanley, E. R., et al., Journal of Cellular Biochemistry 21 (1983) 151-159; Stanley, E. R., et al., Stem Cells 12 Suppl. 1 (1995) 15-24). The second one is IL-34 (human IL-34; SEQ ID NO: 87) (Hume, D. A., et al., Blood 119 (2012) 1810-1820). Thus in one embodiment the term “CSF-1R ligand” refers to human CSF-1 (SEQ ID NO: 86) and/or human IL-34 (SEQ ID NO: 87).

[0152] For experiments often the active 149 amino acid (aa) fragment of human CSF-1 (aa 53-181 of SEQ ID NO: 86) is used. This active 149 aa fragment of human CSF-1 (aa 53-181 of SEQ ID NO: 86) is contained in all 3 major forms of CSF-1 and is sufficient to mediate binding to CSF-1R (Hume, D. A., et al., Blood 119 (2012) 1810-1820).

[0153] The main biological effects of CSF-1R signaling are the differentiation, proliferation, migration, and survival of hematopoietic precursor cells to the macrophage lineage (including osteoclasts). Activation of CSF-1R is mediated by its CSF-1R ligands, CSF-1 (M-CSF) and IL-34. Binding of CSF-1 (M-CSF) to CSF-1R induces the formation of homodimers and activation of the kinase by tyrosine phosphorylation (Li, W. et al, EMBO Journal. 10 (1991) 277-288; Stanley, E. R., et al., Mol. Reprod. Dev. 46 (1997) 4-10).

[0154] The intracellular protein tyrosine kinase domain is interrupted by a unique insert of a fragment that is also present in the other related RTK class III family members that include the platelet derived growth factor receptors (PDGFR), stem cell growth factor receptor (c-Kit) and Fms-like cytokine receptor (FLT3). In spite of the structural homology among this family of growth factor receptors, they have distinct tissue-specific functions.

[0155] CSF-1R is mainly expressed on cells of the monocytic lineage and in the female reproductive tract and placenta. In addition expression of CSF-1R has been reported in Langerhans cells in skin, a subset of smooth muscle cells (Inaba, T., et al., J. Biol. Chem. 267 (1992) 5693-5699), B cells (Baker, A. H., et al., Oncogene 8 (1993) 371-378) and microglia (Sawada, M., et al., Brain Res. 509 (1990) 119-124). Cells with mutant human CSF-1R (SEQ ID NO: 23) are known to proliferate independently of ligand stimulation.

[0156] As used herein, “binding to human CSF-1R” or “specifically binding to human CSF-1R” or “which binds to human CSF-1R” or “anti-CSF-1R antibody” refers to an antibody specifically binding to the human CSF-1R antigen with a binding affinity of KD-value of 1.0x10^-6 mol/l or lower, in one embodiment of a KD-value of 1.0x10^-7 mol/l or lower. The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIACore®, GE-Healthcare Uppsva, Sweden). Thus an “antibody binding to human CSF-1R” as used herein refers to an antibody specifically binding to the human CSF-1R antigen with a binding affinity of KD 1.0x10^-7 mol/l or lower (in one embodiment 1.0x10^-7 mol/l or 1.0x10^-8 mol/l or lower, in one embodiment 1.0x10^-8 mol/l or 1.0x10^-9 mol/l or lower (in one embodiment 1.0x10^-9 mol/l or 1.0x10^-11 mol/l).}

PD-1/PPD-L1/PD-L2 Pathway:


[0158] PD-1 can be expressed on T cells, B cells, natural killer T cells, activated monocytes and dendritic cells (DCs). PD-1 is expressed by activated, but not by unstimulated human CD4+ and CD8+ T cells, B cells and myeloid cells. This stands in contrast to the more restricted expression of CD28 and CTLA-4. Nishimura et al., Int. Immunol. 8: 773-80 (1996); Boettcher et al., J. Virol. 80: 5532-40 (2006). There are at least 4 variants of PD-1 that have been cloned from activated human T cells, including transcripts lacking (-) exon 2, (ii) exon 3, (iii) exons 2 and 3 or (iv) exons 2 through 4. Nielsen et al., Cell. Immunol. 235: 109-16 (2005). With the exception of PD-1 Δex3, all variants are expressed at similar levels as full length PD-1 in resting peripheral blood mononuclear cells (PBMCs). Expression of all variants is significantly induced upon activation of human T cells with anti-CD3 and anti-CD28. The PD-1 Δex3 variants lacks a transmembrane domain, and resembles soluble CTLA-4, which plays an important role in autoimmunity. Ueda et al., Nature 423: 506-11 (2003). This variant is enriched in the synovial fluid and sera of patients with rheumatoid arthritis. Wan et al., J. Immunol. 177: 8844-50 (2006).

[0159] The two PD-1 ligands differ in their expression patterns. PD-L1 is constitutively expressed on mouse T and B cells, CD8, macrophages, mesenchymal stem cells and bone marrow-derived mast cells. Yamazaki et al., J. Immunol. 169: 5538-45 (2002). PD-L1 is expressed on a wide range of nonhematopoietic cells (e.g., cornea, lung, vascular epithelium, liver nonparenchymal cells, mesenchymal stem cells, pancreatic islets, placental syncytiotrophoblasts, kerati-
nococytes, etc.) [Keir et al., Annu. Rev. Immunol. 26: 677-704 (2008)], and is upregulated on a number of cell types after activation. Both type I and type II interferons IFN’s upregulate PD-L1. Ephthimer et al., Micrornaculization 9: 133-45 (2002); Schreiner et al., J. Neuroimmunol. 155: 172-82 (2004); PD-L1 expression in cell lines is decreased when MDX88, TRAF6 and MEK are inhibited. Liu et al., Blood 110: 296-304 (2007). JAK2 has also been implicated in PD-L1 induction. Lee et al., FEBS Lett. 580: 755-62 (2006); Liu et al., Blood 110: 296-304 (2007). Loss or inhibition of phosphatase and tensin homolog (PTEN), a cellular phosphatase that modified phosphatidylinositol 3-kinase (PI3K) and Akt signaling, increased post-transcriptional PD-L1 expression in cancers. Parusa et al., Nat. Med. 13: 84-88 (2007). [0160] PD-L2 expression is more restricted than PD-L1. PD-L2 is inducibly expressed on DC’s, macrophages, and bone marrow-derived mast cells. PD-L2 is also expressed on about half to two-thirds of resting peritoneal B1 cells, but not on conventional B2 B cells. Zhong et al., Eur. J. Immunol. 37: 2405-10 (2007). PD-L2+ B1 cells bind phosphorylated IκB and may be important for innate immune responses against bacterial antigens. Induction of PD-L2 by IFN-gamma is partially dependent upon NF-κB. Liang et al., Eur. J. Immunol. 33: 2706-16 (2003). PD-L2 can also be induced on monocytes and macrophages by GM-CSF, IL-4 and IFN-gamma. Yamazaki et al., J. Immunol. 169: 5538-45 (2002); Loke et al., PNAS 100:5336-41 (2003). [0161] PD-1 signaling typically has a greater effect on cytokine production than on cellular proliferation, with significant effects on IFN-gamma, TNF-alpha and IL-2 production. PD-1 mediated inhibitory signaling also depends on the strength of the TCR signaling, with greater inhibition delivered at low levels of TCR stimulation. This reduction can be overcome by costimulation through CD28 [Freeman et al., J. Exp. Med. 192: 1027-34 (2000)] or the presence of IL-2 [Carter et al., Eur. J. Immunol. 32: 634-43 (2002)]. [0162] Evidence is mounting that signaling through PD-L1 and PD-L2 may be bidirectional. That is, in addition to modulating TCR or BCR signaling, signaling may also be delivered back to the cells expressing PD-L1 and PD-L2. While treatment of dendritic cells with a naturally human anti-PD-L2 antibody isolated from a patient with Waldenstrom’s macroglobulinemia was not found to upregulate MHC II or B7 costimulatory molecules, such cells did produce greater amount of proinflammatory cytokines, particularly TNF-alpha and IL-6, and stimulated T cell proliferation. Nguyen et al., J. Exp. Med. 196: 1393-98 (2002). Treatment of mice with this antibody also (1) enhanced resistance to transplanted b16 melanoma and rapidly induced tumor-specific CTL. Radhakrishnan et al., J. Immunol. 170: 1830-38 (2003); Radhakrishnan et al., Cancer Res. 64: 4965-72 (2004); Heckman et al., Eur. J. Immunol. 37: 1827-35 (2007); (2) blocked development of airway inflammatory disease in a mouse model of allergic asthma. Radhakrishnan et al., J. Immunol. 173: 1560-65 (2004); Radhakrishnan et al., J. Allergy Clin. Immunol. 116: 668-74 (2005). [0163] Further evidence of reverse signaling into dendritic cells (“DC’s”) results from studies of bone marrow derived DC’s cultured with soluble PD-1 (PD-1 EC domain fused to Ig constant region—“s-PD-1”). Kuipers et al., Eur. J. Immunol. 36: 2472-82 (2006). This sPD-1 inhibited DC activation and increased IL-10 production, in a manner reversible through administration of anti-PD-1. [0164] Additionally, several studies show a receptor for PD-L1 or PD-L2 that is independent of PD-1. B7.1 has already been identified as a binding partner for PD-L1. Butte et al., Immunity 27: 111-22 (2007). Chemical crosslinking studies suggest that PD-L1 and B7.1 can interact through their IgV-like domains. B7.1:PD-L1 interactions can induce an inhibitory signal into T cells. Ligation of PD-L1 on CD4+ T cells by B7.1 or ligation of B7.1 on CD4+ T cells by PD-L1 delivers an inhibitory signal. T cells lacking CD28 and CTLA-4 show decreased proliferation and cytokine production when stimulated by anti-CD3 plus B7.1 coated beads. In T cells lacking all the receptors for B7.1 (i.e., CD28, CTLA-4 and PD-L1), T cell proliferation and cytokine production were no longer inhibited by anti-CD3 plus B7.1 coated beads. This indicates that B7.1 acts specifically through PD-L1 on the T-cell in the absence of CD28 and CTLA-4. Similarly, T cells lacking PD-1 showed decreased proliferation and cytokine production when stimulated in the presence of anti-CD3 plus PD-L1 coated beads, demonstrating the inhibitory effect ofPD-L1 ligation on B7.1 on T cells. When T cells lacking all known receptors for PD-1 (i.e., no PD-1 and B7.1), T cell proliferation was no longer impaired by anti-CD3 plus PD-L1 coated beads. Thus, PD-L1 can exert an inhibitory effect on T cells either through B7.1 or PD-1. [0165] The direct interaction between B7.1 and PD-L1 suggests that the current understanding of costimulation is incomplete, and underscores the significance of the expression of these molecules on T cells. Studies of PD-L1/-/- T cells indicate that PD-L1 on T cells can downregulate T cell cytokine production. Latchman et al., Proc. Natl. Acad. Sci. USA 101: 10691-96 (2004). Because both PD-L1 and B7.1 are expressed on T cells, B cells, DC’s and macrophages, there is the potential for directional interactions between B7.1 and PD-L1 on these cell types. Additionally, PD-L1 on non-hematopoietic cells may interact with B7.1 as well as PD-L1 on T cells, raising the question of whether PD-L1 is involved in their regulation. One possible explanation for the inhibitory effect of B7.1:PD-L1 interaction is that T cell PD-L1 may trap or segregate away APC B7.1 from interaction with CD28. [0166] As a result, the antagonism of signaling through PD-L1, including blocking PD-L1 from interacting with either PD-1, B7.1 or both, thereby preventing PD-L1 from sending a negative co-stimulatory signal to T-cells and other antigen presenting cells is likely to enhance immunity in response to infection (e.g., acute and chronic) and tumor immunity. In addition, the anti-PD-1 antibodies of the present invention, may be combined with antagonists of other components of PD-1:PD-L1 signaling, for example, antagonist anti-PD-1 and anti-PD-L2 antibodies. [0167] The term “human PD-L1”, refers to the human protein PD-L1 (SEQ ID NO: 88, PD-L1 signaling typically). As used herein, “binding to human PD-L1” or “specifically binding to human PD-L1” or “which binds to human PD-L1” or “anti-PD-L1 antibody” refers to an antibody specifically binding to the human PD-L1 antigen with a binding affinity of KD-value of 1.0x10^-8 mol/l or lower, in one embodiment of a KD-value of 1.0x10^-9 mol/l or lower. The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE-Healthcare Uppsala, Sweden). Thus,”an antibody binding to human PD-L1” as used herein refers to an antibody specifically binding to the human PD-L1 antigen with a binding affinity of KD 1.0x10^-7 mol/l or lower (in one embodiment 1.0x10^-8 mol/
1.0×10^{-13} mol/l), in on embodiment of a KD 1.0×10^{-9} mol/l or lower (in one embodiment 1.0×10^{-10} mol/l or lower).

[0168] In one embodiment the antibody which binds to human CSF-1R used in the combination therapy described herein is selected from the group consisting of hMab 2F11-c11, hMab 2F11-d8, hMab 2F11-e7, hMab 2F11-f12, and hMab 2F11-g1.

[0169] These antibodies are described in WO2011/070024 and are characterized in comprising the following VH and VL sequences as described herein:

<table>
<thead>
<tr>
<th>anti-CSF-1R antibody</th>
<th>amino acid sequence of the heavy chain variable domain VH, SEQ ID NO:</th>
<th>amino acid sequence of the light chain variable domain VL, SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>hMab 2F11-c11</td>
<td>23</td>
<td>24</td>
</tr>
<tr>
<td>hMab 2F11-d8</td>
<td>31</td>
<td>32</td>
</tr>
<tr>
<td>hMab 2F11-e7</td>
<td>39</td>
<td>40</td>
</tr>
<tr>
<td>hMab 2F11-f12</td>
<td>47</td>
<td>48</td>
</tr>
<tr>
<td>hMab 2F11-g1</td>
<td>55</td>
<td>56</td>
</tr>
</tbody>
</table>

[0170] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy described herein is selected from the group consisting of:


[0171] These antibodies are described in WO 2010/77634 (sequences are shown in FIG. 11 of WO 2010/77634) and are characterized in comprising the following VH and VL sequences as described herein:

<table>
<thead>
<tr>
<th>anti-PD-L1 antibody</th>
<th>amino acid sequence of the heavy chain variable domain VH, SEQ ID NO:</th>
<th>amino acid sequence of the light chain variable domain VL, SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>243.55.S70</td>
<td>89</td>
<td>92</td>
</tr>
<tr>
<td>243.55.H11</td>
<td>90</td>
<td>93</td>
</tr>
<tr>
<td>243.55.H12</td>
<td>90</td>
<td>94</td>
</tr>
<tr>
<td>243.55.H37</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>243.55.H70</td>
<td>90</td>
<td>96</td>
</tr>
<tr>
<td>243.55.I89</td>
<td>90</td>
<td>97</td>
</tr>
<tr>
<td>243.55.S1</td>
<td>90</td>
<td>98</td>
</tr>
<tr>
<td>243.55.5</td>
<td>90</td>
<td>99</td>
</tr>
<tr>
<td>243.55.8</td>
<td>90</td>
<td>100</td>
</tr>
<tr>
<td>243.55.30</td>
<td>90</td>
<td>101</td>
</tr>
<tr>
<td>243.55.34</td>
<td>90</td>
<td>102</td>
</tr>
<tr>
<td>243.55.S37</td>
<td>90</td>
<td>103</td>
</tr>
<tr>
<td>243.55.40</td>
<td>90</td>
<td>104</td>
</tr>
<tr>
<td>243.55.S1</td>
<td>90</td>
<td>105</td>
</tr>
<tr>
<td>243.55.62</td>
<td>90</td>
<td>106</td>
</tr>
<tr>
<td>243.55.84</td>
<td>91</td>
<td>107</td>
</tr>
</tbody>
</table>

[0172] In one embodiment of the invention the antibody which binds to human CSF-1R used in the combination therapy described herein is characterized in comprising:

[0173] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0174] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0175] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0176] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0177] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56; and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising:

[0178] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

[0179] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

[0180] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

[0181] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

[0182] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

[0183] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

[0184] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

[0185] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

[0186] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

[0187] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

[0188] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

[0189] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

[0190] m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

[0191] n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

[0192] o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

[0193] p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107, or

[0194] In one embodiment the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising
[0195] a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24.

[0196] In one embodiment the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0197] a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32.

[0198] In one embodiment the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0199] a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40.

[0200] In one embodiment the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0201] a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48.

[0202] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

[0203] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93.

[0204] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94.

[0205] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95.

[0206] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96.

[0207] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97.

[0208] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98.

[0209] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99.

[0210] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100.

[0211] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101.

[0212] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102.

[0213] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103.

[0214] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104.

[0215] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105.

[0216] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106.

[0217] In one embodiment the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

[0218] In one preferred embodiment of the invention the antibody which binds to human CSF-1R used in the combination therapy described herein is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

[0219] The term “epitope” denotes a protein determinant of human CSF-1R or PD-L1 capable of specifically binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually epitopes have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that the binding to the former but not the latter is lost in the presence of denaturing solvents.

[0220] The “variable domain” (light chain variable domain VL, heavy chain variable domain VH) as used herein denotes each of the pair of light and heavy chain domains which are involved directly in binding the antibody to the antigen. The variable light and heavy chain domains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three “hypervariable regions” (or complementary determin
ing regions, CDRs). The framework regions adopt a beta-sheet conformation and the CDRs may form loops connecting the beta-sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site. The antibody’s heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.

[0221] The term “antigen-binding portion of an antibody” when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding. The antigen-binding portion of an antibody comprises amino acid residues from the “complementary determining regions” or “CDRs”. “Framework” or “FR” regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chain variable domains of an antibody comprise from N- to C-terminus the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. Especially, CDR3 of the heavy chain is the region which contributes most to antigen binding and defines the antibody’s properties. CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991) and/or those residues from a “hypervariable loop”.

[0222] The terms “nucleic acid” or “nucleic acid molecule”, as used herein, are intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.

[0223] The term “amino acid” as used within this application denotes the group of naturally occurring carboxy alpha- amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

[0224] The “Fc part” of an antibody is not involved directly in binding of an antibody to an antigen, but exhibit various effector functions. A “Fc part of an antibody” is a term well known to the skilled artisan and defined on the basis of papain cleavage of antibodies. Depending on the amino acid sequence of the constant region of their heavy chains, antibodies or immunoglobulins are divided in the classes: IgA, IgD.

[0225] IgG, IgM, and several of these may be further divided into subclasses (isotypes), e.g. IgG1, IgG2, IgG3, and IgG4, IgA1, and IgA2. According to the heavy chain constant regions the different classes of immunoglobulins are called a, δ, ε, γ, and μ, respectively. The Fe part of an antibody is directly involved in ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-depndent cytotoxicity) based on complement activation, C1 q binding and Fc receptor binding. Complement activation (CDC) is initiated by binding of complement factor C1q to the Fc part of most IgG antibody subclasses. While the influence of an antibody on the complement system is dependent on certain conditions, binding to C1q is caused by defined binding sites in the Fc part. Such binding sites are known in the state of the art and described e.g. by Boeckle, R. J., et al., Nature 282 (1979) 742-743; Lukas, T. J., et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R., and Cebra, J. J., Mol. Immunol. 16 (1979) 907-917; Burton, D. R., et al., Nature 288 (1980) 338-344; Thrommesen, J. E., et al., Mol. Immunol. 37 (2000) 995-1004; Ishigoe, F. E., et al., J. Immunol. 164 (2000) 1378-1384; Hazen, M., et al., J. Virology 75 (2001) 12161-12168; Morgan, A., et al., Immunology 86 (1995) 319-324; EP 0 307 434. Such binding sites are e.g. L243, L235, D270, N297, E318, K320, K322, P331 and P329 (numbering according to EU index of Kabat, E. A., see below). Antibodies of subclass IgG1, IgG2 and IgG3 usually show complement activation and C1q and C3 binding, whereas IgG4 do not activate the complement system and do not bind C1q and C3.

[0226] In one embodiment the antibody according to the invention comprises an Fc part derived from human origin and preferably all other parts of the human constant regions. As used herein the term “Fc part derived from human origin” denotes a Fc part which is either a Fc part of a human antibody of the subclass IgG1, IgG2, IgG3 or IgG4, preferably a Fc part from human IgG1 subclass, a mutated Fc part from human IgG1 subclass (in one embodiment with a mutation on L234A/L235A), a Fc part from human IgG4 subclass or a mutated Fc part from human IgG4 subclass (in one embodiment with a mutation on S228P). In one preferred embodiment the human heavy chain constant region is SEQ ID NO: 58 (human IgG1 subclass), in another preferred embodiment the human heavy chain constant region is SEQ ID NO: 59 (human IgG1 subclass with mutations L234A and L235A), in another preferred embodiment the human heavy chain constant region is SEQ ID NO: 60 (human IgG4 subclass), and in another preferred embodiment the human heavy chain constant region is SEQ ID NO: 61 (human IgG4 subclass with mutation S228P). In one embodiment said antibodies have reduced or minimal effector function. In one embodiment the minimal effector function results from an effectorless Fc mutation. In one embodiment the effectorless Fc mutation is L234A/L235A or L234A/L235A/P292G or N297A or D265A/N297A. In one embodiment the effectorless Fc mutation is selected for each of the antibodies independently of each other from the group comprising (consisting of) L234A/L235A, L234A/L235A/P292G, N297A and D265A/N297A.

[0227] In one embodiment the antibodies described herein are of human IgG class (i.e. of IgG1, IgG2, IgG3 or IgG4 subclass).

[0228] In a preferred embodiment the antibodies described herein are of human IgG1 subclass or of human IgG4 subclass. In one embodiment the desired herein are of human IgG1 subclass. In one embodiment the antibodies described herein are of human IgG4 subclass.

[0229] In one embodiment the antibody described herein is characterized in that the constant chains are of human origin. Such constant chains are well known in the state of the art and e.g. described by Kabat, E. A., (see e.g. Johnson, G. and Wu, T. I., Nucleic Acids Res. 28 (2000) 214-218). For example, a useful human heavy chain constant region comprises an amino acid sequence of SEQ ID NO: 58. For example, a useful human light chain constant region comprises an amino acid sequence of a kappa-light chain constant region of SEQ ID NO: 57.

[0230] The invention comprises a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of an antibody according to the invention.
[0231] The invention comprises the use of an antibody according to the invention for the described therapy.

[0232] One preferred embodiment of the invention are the CSF-1R antibodies of the present invention for use in the treatment of “CSF-1R mediated diseases” or the CSF-1R antibodies of the present invention for use for the manufacture of a medicament in the treatment of “CSF-1R mediated diseases”, which can be described as follows:


[0234] Pigmented villonodular synovitis (PVNS) and Tenosynovial Giant cell tumors (TGTG) can occur as a result of a bone cancer that expresses the M-CSF gene to a collagen gene COL6A3 and results in overexpression of M-CSF (West, R. B., et al., Proc. Natl. Acad. Sci. USA 103 (2006) 690-695). A landscape effect is proposed to be responsible for the resulting tumor mass that consists of monocytic cells attracted by cells that express M-CSF. TGTGs are smaller tumors that can be relatively easily removed from fingers where they are mainly found in PVNS is more aggressive as it can recur in large joints and is not as easily controlled surgically.

[0235] The second mechanism is based on blocking signal through M-CSF/CSF-1R at metastatic sites in bone which induces osteocalcogenesis, bone resorption and osteolytic bone lesions. Breast, multiple myeloma and lung cancers are examples of cancers that have been found to metastasize to the bone and cause osteolytic bone disease resulting in skeletal complications. M-CSF released by tumor cells and stroma induces the differentiation of hematopoietic myeloid monocyte progenitors to mature osteoclasts in collaboration with the receptor activator of nuclear factor kappa-B ligand-RANKL. During this process, M-CSF acts as a permissive factor by giving the survival signal to osteoclasts (Tanaka, S., et al., J. Clin. Invest. 91 (1993) 257-263) Inhibition of CSF-1R activity during osteoclast differentiation and maturation with an anti-CSF-1R antibody is likely to prevent unbalanced activity of osteoclasts that cause osteolytic disease and the associated skeletal related events in metastatic disease. Whereas breast, lung cancer and multiple myeloma typically result in osteolytic lesions, metastasis to the bone in prostate cancer initially has an osteoblastic appearance in which increased bone forming activity results in ‘woven bone’ which is different from typical lamellar structure of normal bone. During disease progression bone lesions display a significant osteolytic component as well as high serum levels of bone resorption and suggests that anti-resorptive therapy may be useful. Bisphosphonates have been shown to inhibit the formation of osteolytic lesions and increase the number of skeletal-related events only in men with hormone-refractory metastatic prostate cancer but at this point their effect on osteolytic lesions is controversial and bisphosphonates have not been beneficial in preventing bone metastasis or hormone responsive prostate cancer to date. The effect of anti-resorptive agents in mixed osteolytic/osteoblastic prostate cancer is still being studied in the clinic (Choueiri, M. B., et al., Cancer Metastasis Rev. 25 (2006) 601-609; Vessella, R. L. and Corey, E., Clin. Cancer Res. 12 (20 Pt 2) (2006) 6255-6290).

[0236] The third mechanism is based on the recent observation that tumor associated macrophages (TAM) found in solid tumors of the breast, prostate, ovarian and cervical cancers correlated with poor prognosis (Bingle, L., et al., J. Pathol. 196 (2002) 254-265; Pollard, J. W., Nat. Rev. Cancer 4 (2004) 71-78). Macrophages are recruited to the tumor by M-CSF and other chemokines. The macrophages then contribute to tumor progression through the secretion of angiogenic factors, proteases and other growth factors and cytokines and may be blocked by inhibition of CSF-1R signaling. Recently it was shown by Zhang et al (Zhang, K., et al., Cancer Res. 67 (2007) 1038-1045) that expression of sIRNA of Tumor necrosis factor alpha (TNF alpha), M-CSF or the combination of both would reduce tumor growth in a mouse xenograft model between 34% and 50% after intratumoral injection of the respective sIRNA. sIRNA targeting the TNF alpha secreted by the human SW620 cells reduced mouse M-CSF levels and led to reduction of macrophages in the tumor. In addition treatment of MCF7 tumor xenografts with an antigen binding fragment directed against M-CSF did result in 40% tumor growth inhibition, reversed the resistance to chemotherapeutics and improved survival of the mice when given in combination with chemotherapeutics (Paulus, P., et al., Cancer Res. 66 (2006) 4349-4356).

[0237] TAMs are only one example of an emerging link between chronic inflammation and cancer. There is additional evidence for a link between inflammation and cancer as many chronic diseases are associated with an increased risk of cancer, cancers arise at sites of chronic inflammation, chemical mediators of inflammation are found in many cancers; deletion of the cellular or chemical mediators of inflammation inhibits development of experimental cancers and long-term use of anti-inflammatory agents reduce the risk of some cancers. A link to cancer exists for a number of inflammatory conditions among those Helicobacter pylori induced gastritis for gastric cancer, Schistosomiasis for bladder cancer, HIVX for Kaposi’s sarcoma, endometriosis for ovarian cancer and prostatitis for prostate cancer (Balkwell, F., et al., Cancer Cell 7 (2005) 211-217). Macrophages are key cells in chronic inflammation and respond differentially to their microenvironment. There are two types of macrophages that are considered extremes in a continuum of functional states: M1 macrophages are involved in Type 1 reactions. These reactions involve the activation by microbial products and consequent killing of pathogenic microorganisms that result in reactive oxygen intermediates. On the other end of the extreme are M2 macrophages...
replications involved in Type 2 reactions that promote cell proliferation, tune inflammation and adaptive immunity and promote tissue remodeling, angiogenesis and repair (Mantovani, A., et al., Trends Immunol. 25 (2004) 677-686). Chronic inflammation resulting in established neoplasia is usually associated with M2 macrophages. A pivotal cytokine that mediates inflammatory reactions is TNF alpha that true to its name can stimulate anti-tumor immunity and hemorrhagic necrosis at high doses but has also recently been found to be expressed by tumor cells and acting as a tumor promoter (Zins, K., et al., Cancer Res. 67 (2007) 1038-1045; Balkwill, F., Cancer Metastasis Rev. 25 (2006) 409-416). The specific role of macrophages with respect to the tumor still needs to be better understood including the potential spatial and temporal dependence on their function and the relevance to specific tumor types.

[0238] Thus one embodiment of the invention are the CSF-1R antibodies described herein in for use in the treatment of cancer in combination with an anti-PD-L1 antibody as described herein. The term “cancer” as used herein may be, for example, lung cancer, non small cell lung cancer (NSCLC) cancer, bronchioloalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, retinal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumors, brain stem glioma, glioblastoma multiforme, astrocytomas, schwannomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma, lymphoma, lymphocytic leukemia, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers. In one preferred embodiment such cancer is a breast cancer, colorectal cancer, melanoma, head and neck cancer, lung cancer or prostate cancer. In one preferred embodiment such cancer is a breast cancer, ovarian cancer, cervical cancer, lung cancer or prostate cancer. In another preferred embodiment such cancer is breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric carcinoma cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphoma, myeloma. In one preferred embodiment such cancers are further characterized by CSF-1 or CSF-1R expression or overexpression. One further embodiment the invention are the CSF-1R antibodies of the present invention for use in the simultaneous treatment of primary tumors and new metastases. Thus another embodiment of the invention is the CSF-1R antibodies of the present invention for use in the treatment of periodontitis, histiocytosis X, osteoporosis, Paget’s disease of bone (PDB), bone loss due to cancer therapy, periprosthetic osteolysis, glucocorticoid-induced osteoporosis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, inflammatory arthritides, and inflammation.


[0240] Histiocytosis X (also called Langerhans cell histiocytosis, LCH) is a proliferative disease of Langerhans dendritic cells that appear to differentiate into osteoclasts in bone and extra osseous LCH lesions. Langerhans cells are derived from circulating monocytes. Increased levels of M-CSF that have been measured in sera and lesions where found to correlate with disease severity (da Costa, C. E., et al., J. Exp. Med. 201 (2005) 687-693). The disease occurs primarily in a pediatric patient population and has to be treated with chemotherapy when the disease becomes systemic or is recurrent.

[0241] The pathophysiology of osteoporosis is mediated by loss of bone forming osteoblasts and increased osteoclast dependent bone resorption. Supporting data has been described by Cenci et al showing that an anti-M-CSF antibody injection preserves bone density and inhibits bone resorption in ovariectomized mice (Cenci, S., et al., J. Clin. Invest. 105 (2000) 1279-1287). Recently a potential link between postmenopausal bone loss due to estrogen deficiency was identified and found that the presence of TNF alpha inducing T-cell affected bone metabolism (Ruggia, C., et al., Minerva Med. 95 (2004) 125-132). A possible mechanism could be the induction of M-CSF by TNF alpha in vivo. An important role for M-CSF in TNF-alpha-induced osteoclastogenesis was confirmed by the effect of an antibody directed against M-CSF that blocked the TNF alpha induced osteolysis in mice and thereby made inhibitors of CSF-1R signaling potential targets for inflammatory arthritis (Kitaura, H., et al., J. Clin. Invest. 115 (2005) 3418-3427).

[0242] Paget’s disease of bone (PDB) is the second most common bone metabolism disorder after osteoporosis in which focal abnormalities of increased bone turnover lead to complications such as bone pain, deformity, pathological fractures and deafness. Mutations in four genes have been identified that regulate normal osteoclast function and predispose individuals to PDB and related disorders: insertion mutations in TNFRSF11A, which encodes receptor activator of nuclear factor (NF) kappaB (RANK)-a critical regulator of osteoclast function, inactivating mutations of TNFRSF11B which encodes osteoprotegerin (a decoy receptor for RANK ligand), mutations of the sequestosome 1 gene (SQSTM1), which encodes an important scaffold protein in the NF-kappaB pathway and mutations in the valosin-containing protein (VCP) gene. This gene encodes VCP, which has a role in targeting the inhibitor of NF-kappaB for degradation by the proteasome (Daroszewska, A. and Ralston, S. H., Nat. Clin. Pract. Rheumatol. 2 (2006) 270-277). Targeted CSF-1R inhibitors provide an opportunity to block the deregulation of the RANKL signaling indirectly and add an additional treatment option to the currently used bisphosphonates.

[0243] Cancer therapy induced bone loss especially in breast and prostate cancer patients is an additional indication where a targeted CSF-1R inhibitor could prevent bone loss (Lester, J. E., et al., Br. J. Cancer 94 (2006) 30-35). With the improved prognosis for early breast cancer the long-term consequences of the adjuvant therapies become more important as some of the therapies including chemotherapy, irradiation, aromatase inhibitors and ovari ablation affect bone

[0244] Targeted inhibition of CSF-1R signaling is likely to be beneficial in other indications as well when targeted cell types include osteoclasts and macrophages e.g. treatment of specific complications in response to joint replacement as a consequence of rheumatoid arthritis. Implant failure due to peri-prosthetic bone loss and consequent loosening of prostheses is a major complication of joint replacement and requires repeated surgery with high socioeconomic burdens for the individual patient and the health-care system. To date, there is no approved drug therapy to prevent or inhibit peri-prosthetic osteolysis (Drees, P., et al., Nat. Clin. Pract. Rheumatol. 3 (2007) 165-171).

[0245] Glucocorticoid-induced osteoporosis (GIOP) is another indication in which a CSF-1R inhibitor could prevent bone loss after longterm glucocorticosteroid use that is given as a result of various conditions among those chronic obstructive pulmonary disease, asthma and rheumatoid arthritis (Guzman-Clark, J. R., et al., Arthritis Rheum. 57 (2007) 140-146; Feldstein, A. C., et al., Osteoporos. Int. 16 (2005) 2168-2174).

[0246] Rheumatoid arthritis, psoriatic arthritis and inflammatory arthritis are in itself potential indications for CSF-1R signaling inhibitors in that they consist of a macrophage component and to a varying degree bone destruction (Ritchlin, C. T., et al., J. Clin. Invest. 111 (2003) 821-831). Osteoarthritis and rheumatoid arthritis are inflammatory autoimmune disease caused by the accumulation of macrophages in the connective tissue and infiltration of macrophages into the synovial fluid, which is at least partially mediated by M-CSF. Campbell, I., et al., J. Lenkoc. Biol. 68 (2000) 144-150, demonstrated that M-CSF is produced by human joint tissue cells (chondrocytes, synovial fibroblasts) in vitro and is found in synovial fluid of patients with rheumatoid arthritis, suggesting that it contributes to the synovial tissue proliferation and macrophage infiltration which is associated with the pathogenesis of the disease. Inhibition of CSF-1R signaling is likely to control the number of macrophages in the joint and alleviate the pain from the associated bone destruction. In order to minimize adverse effects and to further understand the impact of the CSF-1R signaling in these indications, one method is to specifically inhibit CSF-1R without targeting a myriad other kinases, such as Raf kinase.


[0248] Expression and signaling of M-CSF and CSF-1R is found in activated microglia. Microglia, which are resident macrophages of the central nervous system, can be activated by various insults, including infection and traumatic injury. M-CSF is considered a key regulator of inflammatory responses in the brain and M-CSF levels increase in HIV-1, encephalitis, Alzheimer’s disease (AD) and brain tumors. Microgliosis as a consequence of autocrine signaling by M-CSF/CSF-1R results in induction of inflammatory cytokines and nitric oxides being released as demonstrated by e.g. using an experimental neuronal damage model (Hao, A. J., et al., Neuroscience 112 (2002) 889-900; Murphy, G. M., Jr., et al., J. Biol. Chem. 273 (1998) 20967-20971). Microglia that have increased expression of CSF-1R are found to surround plaques in AD and in the amyloid precursor protein V717F transgenic mouse model of AD (Murphy, G. M., Jr., et al., Am. J. Pathol. 157 (2000) 895-904). On the other hand op/op mice with fewer microglia in the brain resulted in fibrillar deposition of A-beta and neuronal loss compared to normal control suggesting that microglia do have a neuroprotective function in the development of AD lacking in the op/op mice (Kaku, M., et al., Brain Res. Brain Res. Protoc. 12 (2003) 104-108).

[0249] Expression and signaling of M-CSF and CSF-1R is associated with inflammatory bowel disease (IBD) (WO 2005/046657). The term “inflammatory bowel disease” refers to serious, chronic disorders of the intestinal tract characterized by chronic inflammation at various sites in the gastrointestinal tract, and specifically includes ulcerative colitis (UC) and Crohn’s disease.

[0250] Thus another embodiment of the invention are the CSF-1R antibodies being characterized by the above mentioned amino acid sequences and amino acid sequence in combination with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequences and amino acid sequence for use in the treatment of periodontitis, histiocytosis X, osteoporosis, Paget’s disease of bone (PDOb), bone loss due to cancer therapy, periprosthetic osteolysis, glucocorticoid-induced osteoporosis, rheumatoid arthritis, psiratic arthritis, osteoarthritis, inflammatory arthritides, and inflammation.

[0251] The invention comprises the combination therapy with an antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequence fragments and amino acid sequence fragments for the treatment of cancer.

[0252] The invention comprises the combination therapy with an antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for the treatment of bone loss.

[0253] The invention comprises the combination therapy with an antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for the prevention or treatment of metastasis.

[0254] The invention comprises the combination therapy of antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for treatment of inflammatory diseases.
The invention comprises the combination therapy of antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments with an anti-PD-L1 antibody being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for use in stimulating an immune response or function, such as T cell activity.

The invention comprises the use of an antibody characterized in comprising the antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for the combination treatment of cancer with an anti-PD-L1 antibody or alternatively for the manufacture of a medicament for the combination treatment of cancer with an anti-PD-L1 antibody as described herein.

The invention comprises the use of an antibody characterized in comprising the antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments, for the combination treatment of bone loss with an anti-PD-L1 antibody as described herein.

The invention comprises the use of an antibody characterized in comprising the antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for the prevention or treatment of metastasis in the combination with an anti-PD-L1 antibody as described herein or alternatively for the manufacture of a medicament for the prevention or treatment of metastasis in the combination with an anti-PD-L1 antibody as described herein.

The invention comprises the combination therapy of antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for combination treatment of inflammatory diseases with an anti-PD-L1 antibody as described herein or alternatively for the manufacture of a medicament for the combination treatment of inflammatory diseases with an anti-PD-L1 antibody as described herein.

The invention comprises the use of an antibody characterized in comprising the antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for use in treating or delaying progression of an immune related disease such as tumor immunity in combination with an anti-PD-L1 antibody as described herein or alternatively for the manufacture of a medicament for use in treating or delaying progression of an immune related disease such as tumor immunity in combination with an anti-PD-L1 antibody as described herein.

The invention comprises the use of an antibody characterized in comprising the antibody binding to human CSF-1R being characterized by the above mentioned amino acid sequences and amino acid sequence fragments for use in stimulating an immune response or function, such as T cell activity in combination with an anti-PD-L1 antibody as described herein or alternatively for the manufacture of a medicament for use in stimulating an immune response or function, such as T cell activity in combination with an anti-PD-L1 antibody as described herein.

In one preferred embodiment of the invention, the antibody which binds to human CSF-1R used in the above described combination treatments and medical uses of different diseases is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, and the antibody which binds to human PD-L1 used in such combination treatments is characterized in comprising a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

The antibodies described herein are preferably produced by recombinant means. Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity. For the protein expression, nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells, such as CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells, and the antibody is recovered from the cells (from the supernatant or cell lysates).


The antibodies may be present in whole cells, in a cell lysate, or in a partially purified, or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins. The use of an extraction technique including alkaline/SDS treatment, CaCl2 banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See Ausubel, F., et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).


The heavy and light chain variable domains according to the invention are combined with sequences of promoter, translation initiation, constant region, 3′ untranslated region, polyadenylation, and transcription termination to
form expression vector constructs. The heavy and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a single host cell expressing both chains. (0270) The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, enhancers and polyadenylation signals.

(0271) Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

(0272) The monoclonal antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA and RNA encoding the monoclonal antibodies are readily isolated and sequenced using conventional procedures. The hybridoma cells can serve as a source of such DNA and RNA. Once isolated, the DNA may be inserted into expression vectors, which are then transfected into host cells such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.

(0273) As used herein, the expressions “cell”, “cell line”, and “cell culture” are used interchangeably and all such designations include progeny. Thus, the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.

(0274) In another aspect, the present invention provides a composition, e.g. a pharmaceutical composition, containing one or a combination of monoclonal antibodies, or the anti-gen-binding portion thereof, of the present invention, formulated together with a pharmaceutically acceptable carrier.

(0275) As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for injection or infusion.

(0276) A composition of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.

(0277) Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art. In addition to water, the carrier can be, for example, an isotonic buffered saline solution.

(0278) Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

(0279) Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient (effective amount). The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

(0280) The term “a method of treating” or its equivalent, when applied to, for example, cancer refers to a procedure or course of action that is designed to reduce or eliminate the number of cancer cells in a patient, or to alleviate the symptoms of a cancer. “A method of treating” cancer or another proliferative disorder does not necessarily mean that the cancer cells or other disorder will, in fact, be eliminated, that the number of cells or disorder will, in fact, be reduced, or that the symptoms of a cancer or other disorder will, in fact, be alleviated. Often, a method of treating cancer will be performed even with a low likelihood of success, but which, given the medical history and estimated survival expectancy of a patient, is nevertheless deemed to induce an overall beneficial course of action.

(0281) The terms “administered in combination with” or “co-administration”, “co-administering”, “combination therapy” or “combination treatment” refer to the administration of the anti-CSF-1R as described herein, and the anti-PD-L1 antibody as described herein e.g. as separate formulations/applications (or as one single formulation/application). The co-administration can be simultaneous or sequential in either order, wherein preferably there is a time period while both (or all) active agents simultaneously exert their biological activities. Said antibody and said further agent are co-administered either simultaneously or sequentially (e.g. intravenously (i.v.) through a continuous infusion. When both therapeutic agents are co-administered sequentially the dose is administered either on the same day in two separate administrations, or one of the agents is administered on day 1 and the second is co-administered on day 2 to day 7, preferably on day 2 to 4. Thus in one embodiment the term “sequentially” means within 7 days after the dose of the first component, preferably within 4 days after the dose of the first component; and the term “simultaneously” means at the same time. The terms “co-administration” with respect to the maintenance doses of anti-CSF-1R antibody and/or anti-PD-L1 antibody mean that...
the maintenance doses can be either co-administered simul-
taneously, if the treatment cycle is appropriate for both drugs, e.g. every week. Or the further agent is e.g. administered e.g. every first to third day and said antibody is administered every week. Or the maintenance doses are co-administered sequen-
tially, either within one or within several days.

[0282] It is self-evident that the antibodies are administered to the patient in a “therapeutically effective amount” (or sim-
ply “effective amount”) which is the amount of the respective compound or combination that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.

[0283] The amount of co-administration and the timing of co-
administration will depend on the dose type (species, gender, age, weight, etc) and condition of the patient being treated and the severity of the disease or condition being treated. Said anti-anti-CSF-1R antibody and further agent are suitably co-
administered to the patient at one time or over a series of treat-
ments e.g. on the same day or on the day after.

[0284] Depending on the type and severity of the disease, about 0.1 mg/kg to 50 mg/kg (e.g. 0.1-20 mg/kg) of said anti-anti-CSF-1R antibody and/or anti-PD-L1 antibody is an ini-
tial candidate dosage for co-administration of both drugs to the patient. The invention comprises the use of the antibodies according to the invention for the treatment of a patient suf-
ferring from cancer, especially from colon, lung or pancreas cancer.

[0285] Depending on the type and severity of the disease, about 0.1 mg/kg to 50 mg/kg (e.g. 0.1-20 mg/kg) of said anti-anti-CSF-1R antibody and/or anti-PD-L1 antibody is an ini-
tial candidate dosage for co-administration of both drugs to the patient. The invention comprises the use of the antibodies according to the invention for the treatment of a patient suf-
ferring from cancer, especially from colon, lung or pancreas cancer.

[0286] In addition to the anti-anti-CSF-1R antibody in combi-
nation with the anti-PD-L1 antibody also a chemotherapeutic agent can be administered.

[0287] In one embodiment such additional chemotherapeut-
ic agents, which may be administered with anti-anti-CSF-1R antibody as described herein and the anti-PD-L1 antibody as described herein, include, but are not limited to, anti-neoplastic agents including alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); Temodal™ (temozolomide), ethylen-
imines/methylmelamines such as triethylene melamine (TEM), triethylene, thiophosphoramide (thiotepa), hexam-
ethylenelamine (HMM, altretamine); alkyl sulfonates such as busulphan; triazines such as dacarbazine (DTIC); antimetabo-
lites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil (5FU), fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-aza-cytidine, 2,2′-difluoro-deoxyx-
tidine, purine analogs such as 6-merca-zo-topurine, 6-thioguanine, azathioprine, 1-deoxy-coformycin (pentosta-
tin), erythrohydroxynonyladenine (EHNA), fluorarabine phophate, and 2-chlorodeoxyadenosine (cladrabine, 2-CA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLH), vin-
cristine, and vincristine, taxotere, estramustine, and estr-
mustine phosphate; pipopodophyllotoxins such as etoposide and
teniposide; antibiotics such as actinomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleo-
mycin, plicamycin (mithramycin), mitomycin C, and acti-
nomycin; enzymes such as L-asparaginase; biological response modifiers such as interferon-alpha, IL-2, G-CSF and GM-CSF; miscellaneous agents including platinum coordina-
tion complexes such as oxaliplatin, cisplatin and carboplat-
in, anthrancenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydroxylamine derivatives including N-methylhydroxylamine (MHI) and procarbazine, adrenocortical suppressants such as mitotane (o, p-DDD) and aminogluteth-
thimide; hormones and antagonists including adrenocorticoster-
toid antagonists such as prednisone and equivalents, dexam-
ethasone and aminoglutethimide. Gemcitabine™ (gemcitabine), progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogens such as tamoxifen; androgens including testosterone propionate and fluoxymesterone/ equivalents; anti-androgens such as flutamide, gona
dotropin-releasing hormone analogs and leuprolide; and non-steroidal anti-androgens such as flutamide. Therapies targeting epige-
etic mechanism including, but not limited to, histone deacteylase inhibitors, demethylating agents (e.g., Vidaza) and release of transcriptional repression (ATRA) therapies can also be combined with the antigen binding proteins. In one embodiment the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. paclitaxel (Taxol), docetaxel (Taxotere), modified paclitaxel (e.g., Abraxane and Opoxio), doxorubicin, sunitinib (Sutent), sorafenib (Nex-
avar), and other multikinase inhibitors, oxaliplatin, cisplatin and carboplatin, etoposide, gemcitabine, and vinblastine. In one embodiment the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. taxol (paclitaxel), docetaxel (Taxotere), modified paclitaxel (e.g., Abraxane and Opoxio). In one embodiment, the additional chemotherapeutic agent is selected from 5-fluorouracil (5FU), leucovorin, irinotecan, or oxaliplatin. In one embodiment the chemotherapeutic agent is 5-fluorouracil, leucovorin and irinotecan (FOLFOX). In one embodiment, the additional chemotherapeutic agent is selected from 5-fluorouracil, and oxaliplatin (FOLFOX).

[0288] Specific examples of combination therapies with additional chemotherapeutic agents include, for instance, therapies taxanes (e.g., docetaxel or paclitaxel) or a modified paclitaxel (e.g., Abraxane or Opoxio), doxorubicin, capecitabine and/or bevacizumab (Avastin) for the treatment of breast cancer; therapies with carboplatin, oxaliplatin, cispl-
atin, paclitaxel, doxorubicin (or modified doxorubicin (Caen-
lyx or Doxil)), or topotecan (Hycafin) for ovarian cancer, the therapies with a multi-kinase inhibitor, MKI, (Sutent, Nexavar, or 706) and/or doxorubicin for treatment of kidney cancer; therapies with oxaliplatin, cisplatin and/or radiation for the treatment of squamous cell carcinoma; therapies with taxol and/or carboplatin for the treatment of lung cancer.

[0289] Therefore, in one embodiment the additional che-
motherapeutic agent is selected from the group of taxanes (docetaxel or paclitaxel or a modified paclitaxel (Abraxane or Opoxio), doxorubicin, capecitabine and/or bevacizumab for the treatment of breast cancer.

[0290] In one embodiment the CSF-1R antibody/PD-L1 antibody combination therapy is no chemotherapeutic agents are administered.

[0291] The invention comprises also a method for the treat-
ment of a patient suffering from such disease.
[0292] The invention further provides a method for the manufacture of a pharmaceutical composition comprising an effective amount of an antibody according to the invention together with a pharmaceutically acceptable carrier and the use of the antibody according to the invention for such a method.

[0293] The invention further provides the use of an antibody according to the invention in an effective amount for the manufacture of a pharmaceutical agent, preferably together with a pharmaceutically acceptable carrier, for the treatment of a patient suffering from cancer.

[0294] The invention also provides the use of an antibody according to the invention in an effective amount for the manufacture of a pharmaceutical agent, preferably together with a pharmaceutically acceptable carrier, for the treatment of a patient suffering from cancer.

[0295] The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

---

**Description of the Sequences**

<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Description of the Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEQ ID NO: 47</td>
<td>heavy chain variable domain, hMab 2F11-N2</td>
</tr>
<tr>
<td>SEQ ID NO: 48</td>
<td>light chain variable domain, hMab 2F11-N2</td>
</tr>
<tr>
<td>SEQ ID NO: 49</td>
<td>heavy chain CDR3, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 50</td>
<td>light chain CDR2, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 51</td>
<td>light chain CDR1, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 52</td>
<td>light chain CDR3, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 53</td>
<td>light chain CDR2, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 54</td>
<td>light chain CDR1, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 55</td>
<td>heavy chain variable domain, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 56</td>
<td>light chain variable domain, hMab 2F11-g1</td>
</tr>
<tr>
<td>SEQ ID NO: 57</td>
<td>human kappa light chain constant region</td>
</tr>
<tr>
<td>SEQ ID NO: 58</td>
<td>human heavy chain constant region derived from IgG1</td>
</tr>
<tr>
<td>SEQ ID NO: 59</td>
<td>human heavy chain constant region derived from IgG4 mutated on L23MA and 1235A</td>
</tr>
<tr>
<td>SEQ ID NO: 60</td>
<td>human heavy chain constant region derived from IgG4</td>
</tr>
<tr>
<td>SEQ ID NO: 61</td>
<td>human heavy chain constant region derived from IgG4 mutated on S28P</td>
</tr>
<tr>
<td>SEQ ID NO: 62</td>
<td>human wildtype CSF-1R (wt CSF-1R) (including signal sequence)</td>
</tr>
<tr>
<td>SEQ ID NO: 63</td>
<td>human mutant CSF-1R L301S Y99F (including signal sequence)</td>
</tr>
<tr>
<td>SEQ ID NO: 64</td>
<td>human CSF-1R Extracellular Domain (domains D1-D3)</td>
</tr>
<tr>
<td>SEQ ID NO: 65</td>
<td>human CSF-1R fragment delD4</td>
</tr>
<tr>
<td>SEQ ID NO: 66</td>
<td>human CSF-1R fragment domains D1-D3</td>
</tr>
<tr>
<td>SEQ ID NO: 67</td>
<td>signal peptide</td>
</tr>
<tr>
<td>SEQ ID NO: 68</td>
<td>Primer</td>
</tr>
<tr>
<td>SEQ ID NO: 69</td>
<td>light chain CDR3, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 70</td>
<td>light chain CDR2, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 71</td>
<td>light chain CDR1, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 72</td>
<td>light chain CDR3, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 73</td>
<td>light chain CDR2, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 74</td>
<td>light chain CDR1, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 75</td>
<td>heavy chain variable domain, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 76</td>
<td>light chain variable domain, hMab 1G10</td>
</tr>
<tr>
<td>SEQ ID NO: 77</td>
<td>heavy chain CDR3, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 78</td>
<td>light chain CDR2, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 79</td>
<td>light chain CDR1, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 80</td>
<td>light chain CDR3, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 81</td>
<td>light chain CDR2, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 82</td>
<td>light chain CDR1, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 83</td>
<td>heavy chain variable domain, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 84</td>
<td>light chain variable domain, hMab 1H</td>
</tr>
<tr>
<td>SEQ ID NO: 85</td>
<td>human CSF-1R fragment domains D4-D5</td>
</tr>
<tr>
<td>SEQ ID NO: 86</td>
<td>human CSF-1R (including signal sequence)</td>
</tr>
<tr>
<td>SEQ ID NO: 87</td>
<td>human IL-34 (including signal sequence)</td>
</tr>
<tr>
<td>SEQ ID NO: 88</td>
<td>human PD-L1 (including signal sequence)</td>
</tr>
<tr>
<td>SEQ ID NO: 89</td>
<td>heavy chain variable domain VII variant 1, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 90</td>
<td>heavy chain variable domain VII variant 2, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 91</td>
<td>heavy chain variable domain VII variant 3, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 92</td>
<td>light chain variable domain VI variant 1, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 93</td>
<td>light chain variable domain VI variant 2, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 94</td>
<td>light chain variable domain VI variant 3, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 95</td>
<td>light chain variable domain VI variant 4, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 96</td>
<td>light chain variable domain VI variant 5, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 97</td>
<td>light chain variable domain VI variant 6, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 98</td>
<td>light chain variable domain VI variant 7, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 99</td>
<td>light chain variable domain VI variant 8, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 100</td>
<td>light chain variable domain VI variant 9, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 101</td>
<td>light chain variable domain VI variant 10, anti-PD-L1</td>
</tr>
<tr>
<td>SEQ ID NO: 102</td>
<td>light chain variable domain VI variant 11, anti-PD-L1</td>
</tr>
</tbody>
</table>
In the following embodiment of the invention are described:

1. A) An antibody which binds to human CSF-1R wherein the antibody is administered in combination with an antibody which binds to human PD-L1 for use in the treatment of cancer, for use in the prevention or treatment of metastasis, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity; or

2. B) the use of an antibody which binds to human CSF-1R for the manufacture of a medicament for use in the treatment of cancer, for use in the prevention or treatment of metastasis, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity, wherein the antibody is administered in combination with an antibody which binds to human PD-L1;

wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

A) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

B) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

C) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

D) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

E) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

A) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

B) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

C) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

D) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

E) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

F) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

G) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

H) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

I) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

J) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

K) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

L) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

M) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

N) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

O) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

P) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

2. Use of a combination of

A) an antibody which binds to human CSF-1R, comprising

A) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

B) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

C) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

D) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

E) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;
and

B) an antibody which binds to human PD-L1 comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

for the manufacture of a medicament for use in the treatment of cancer, for use in the prevention or treatment of metastasis, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity, wherein the antibody is administered in combination with an antibody which binds to human PD-L1

3. The antibody or use according to any one of embodiments 1 or 2, for use in the treatment of cancer.


5. The antibody or use according to any one of embodiments 1 or 2, for use in the prevention or treatment of metastasis.

6. The antibody or use according to any one of embodiments 1 or 2, for use in the treatment of bone loss.

7. The antibody or use according to any one of embodiments 1 or 2, for use in the treatment of inflammatory diseases.

8. The antibody or use according to any one of embodiments 1 or 2, for use in treating or delaying progression of an immune related disease such as tumor immunity.

9. The antibody or use according to any one of embodiments 1 or 2 for use in stimulating an immune response or function, such as T cell activity.

10. A) An antibody which binds to human CSF-1R wherein the antibody is administered in combination with an antibody which binds to human PD-L1 for use in

i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing tumor cells;

ii) the inhibition of proliferation of tumors with CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing macrophage infiltrate;

iii) the inhibition of cell survival (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or

iv) the inhibition of cell differentiation (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes into macrophages;

or

B) use of an antibody which binds to human CSF-1R for the manufacture of a medicament for use in

i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing tumor cells;

ii) the inhibition of cell proliferation of tumors with CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing macrophage infiltrate;

iii) the inhibition of cell survival (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or

iv) the inhibition of cell differentiation (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes into macrophages;

wherein the antibody is administered in combination with an antibody which binds to human PD-L1;
[0366] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0367] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0368] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0369] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0370] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0371] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0372] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0373] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

[0374] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

[0375] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

[0376] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

[0377] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

[0378] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

[0379] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

[0380] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

[0381] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

[0382] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

[0383] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

[0384] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

[0385] m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

[0386] n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

[0387] o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:90, or

[0388] p) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:107.

[0389] 11. A) An antibody which binds to human CSF-1R, for use in the treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein the anti-CSF-1R antibody is administered in combination with an antibody which binds to human PD-L1, or

[0390] B) use of an antibody which binds to human CSF-1R, for the manufacture of a medicament for use in the treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein the anti-CSF-1R antibody is administered in combination with an antibody which binds to human PD-L1.

[0391] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0392] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0393] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0394] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0395] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0396] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0397] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0398] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

[0399] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

[0400] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

[0401] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

[0402] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

[0403] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

[0404] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
[0405] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
[0406] i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
[0407] j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
[0408] k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or
[0409] l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
[0410] m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
[0411] n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
[0412] o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
[0413] p) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:107.

[0414] 12. The antibody or use according any one of the preceding embodiments,

[0415] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0416] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0417] wherein the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92.

[0418] 13. The antibody or use according any one of the preceding embodiments, characterized in that said antibodies are of human IgG1 subclass or human IgG4 subclass.

[0419] 14. The antibody or use according to any one of the preceding embodiments, characterized in that said antibodies have reduced or minimal effector function.

[0420] 15. The antibody or use according to any one of the preceding embodiments, wherein the minimal effector function results from an effectorless Fc mutation.

[0421] 16. The antibody or use according to any one of the preceding embodiments, wherein the effectorless Fc mutation is L234A/L235A or L234A/L235A/P329G or N297A or D265A/N297A.

[0422] 17. A method for

[0423] i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing tumor cells;

[0424] ii) the inhibition of cell proliferation of tumors with CSF-1R ligand-dependent and/or CSF-1R ligand-independent CSF-1R expressing macrophage infiltrate;

[0425] iii) the inhibition of cell survival (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or

[0426] iv) the inhibition of cell differentiation (in CSF-1R ligand-dependent and/or CSF-1R ligand-independent) CSF-1R expressing macrophages into macrophages;

[0427] wherein an antibody which binds to human CSF-1R, is administered in combination with an antibody which binds to human PD-L1,

[0428] or

[0429] B) a method of treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein an antibody which binds to human CSF-1R is administered in combination with an antibody which binds to human PD-L1,

[0430] wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

[0431] a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

[0432] b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

[0433] c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

[0434] d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

[0435] e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

[0436] and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

[0437] a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

[0438] b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

[0439] c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

[0440] d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

[0441] e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

[0442] f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

[0443] g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

[0444] h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
**Example 1**

Inhibition of CSF-1-Induced CSF-1R Phosphorylation in NIH3T3-CSF-1R Recombinant Cells

[0453] 4.5x10^4 NIH 3T3 cells, retrovirally infected with an expression vector for full-length CSF-1R, were cultured in DMEM (PAACat. No. E15-011), 2 mM L-glutamine (Sigma, Cat. No. G7513), 2 mM Sodium pyruvate, 1x nonessential amino acids, 10% FBS (PAACat. No. A15-049) and 100 μg/ml PenStrep (Sigma, Cat. No. P4333 [10 mg/ml]) until they reached confluence. Thereafter cells were washed with serum-free DMEM media (PAACat. No. E15-011) supplemented with sodium selenite [5 ng/ml] (Sigma, Cat. No. S9133), transferrin [10 μg/ml] (Sigma, Cat. No. T8158), BSA [400 μg/ml] (Roche Diagnostics GmbH, Cat. No. 10735078), 4 mM L-glutamine (Sigma, Cat. No. G7513), 2 mM sodium pyruvate (Gibco, Cat. No. 11360), 1x nonessential amino acids (Gibco, Cat. No. 11140-35), 2-mercaptoethanol [0.05 mM] (Merck, Cat. No. M7522), 100 μg/ml and PenStrep (Sigma, Cat. No. P4333) and incubated in 30 μl of the same medium for 16 hours to allow for receptor up-regulation. 10 μl of diluted anti-CSF-1R antibodies were added to the cells for 1 h. Then cells were stimulated with 10 μl of 100 ng/ml hu CSF-1 (active 149 aa fragment of human CSF-1 (aa 33-181 of SEQ ID NO: 86); Biomol, DE, Cat. No. 60530) for 5 min. After the incubation, supernatant was removed, cells were washed twice with 80 μl of ice-cold PBS and 50 μl of freshly prepared ice-cold lysis buffer (150 mM NaCl/20 mM Tris pH 7.5/1 mM EDTA1/ mM EGTA1/1% Triton X-100) 1 protease inhibitor tablet (Roche Diagnostics GmbH Cat. No. 158170) per 10 μl buffer/10 μl/ml phosphatase inhibitor cocktail 1 (Sigma Cat. No. P-2850, 100x Stock), 10 μl/ml protease inhibitor 1 (Sigma Cat. No. P-5726, 100x Stock) per 10 μl/ml 1 M NaF) was added. After 30 minutes on ice the plates were shaken vigorously on a plate shaker for 3 minutes and then centrifuged 10 minutes at 2200 rpm (Heraeus Megafuge 10).

**Example 2**

Growth Inhibition of NIH3T3-CSF-1R Recombinant Cells in 3D Culture Under Treatment with Anti-CSF-1R Monoclonal Antibodies (CellTitre Glo-Assay)

[0455] NIH 3T3 cells, retrovirally infected with either an expression vector for full-length wildtype CSF-1R (SEQ ID NO: 62) or mutant CSF-1R L301STyr699F (SEQ ID NO: 63), were cultured in DMEM high glucose media (PAACat. Pasching, Austria) supplemented with 2 m L-glutamine, 2 mM sodium pyruvate and non-essential amino acids at 10% fetal bovine serum (Sigma, Taufkirchen, Germany) on polyHEMA (poly(2-hydroxyethylmethacrylate)) (Polysciences, Warrington, PA, USA) treated dishes to prevent adherence to the plastic surface. Cells are seeded in medium replacing serum with 5 mg/ml sodium selenite, 10 mg/ml transferrin, 400 μg/ml BSA and 0.05 mM 2-mercaptoethanol. When treated with 100 ng/ml hu CSF-1 (active 149 aa fragment of human CSF-1 (aa 33-181 of SEQ ID NO: 86); Biomol, DE, Cat. No. 60530) wtCSF-1R (expressing cells form dense spheroids that grow three dimensionally, a property that is called anchorage independence. These spheroids resemble closely the three dimensional architecture and organization of solid tumors in situ. Mutant CSF-1R recombinant cells are able to form spheroids independent of the CSF-1 ligand. The anti-CSF-1R antibody according to the invention hMab 2F11-e7 and the anti-CSF-1R antibodies 1.2.5M (ligand displacing CSF-1R antibody described in WHO 2009/026303, CXL106 (ligand displacing CSF-1R antibody described in WHO 2009/112245), the goat polyclonal anti-CSF-1R antibody ab10676 (abcam), and SC-2-A5 (Santa Cruz Biotech-
nology. US—see also Sherr, C. J. et al., Blood 73 (1989) 1786-1793) and Mab R&D-Systems 3291 were investigated. Reference control Mab R&D-Systems 3291 did not show inhibition of mutant CSF-1R recombinant cell proliferation.

**Example 4**

Inhibition of Human Macrophage Differentiation
Under Treatment with Anti-CSF-1R Monoclonal Antibodies (CellTiterGlo-Assay)

**Example 5**

Inhibition of Human M1 and M2 Macrophage Differentiation Under Treatment with Anti-CSF-1R Monoclonal Antibodies (CellTiterGlo-Assay)

**Table 4**

<table>
<thead>
<tr>
<th>CSF-1R Mab</th>
<th>wtCSF-1R IC50 [μg/ml]</th>
<th>Mutant CSF-1R IC50 [μg/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mab2F11-e7</td>
<td>4.91</td>
<td>0.54</td>
</tr>
<tr>
<td>1.2.SM</td>
<td>1.19</td>
<td>&gt;20 μg/ml (19% inhibition at 20 μg/ml)</td>
</tr>
<tr>
<td>CX2B6</td>
<td>&gt;20 μg/ml (21% inhibition at 20 μg/ml)</td>
<td></td>
</tr>
<tr>
<td>ab10576</td>
<td>14.15</td>
<td>&gt;20 μg/ml (0% inhibition at 20 μg/ml)</td>
</tr>
<tr>
<td>SC 2-A5</td>
<td>16.62</td>
<td>2.56</td>
</tr>
</tbody>
</table>

**Example 3**

Inhibition of Human Macrophage Differentiation
Under Treatment with Anti-CSF-1R Monoclonal Antibodies (CellTiterGlo-Assay)

**Example 4**

**Table 4**

<table>
<thead>
<tr>
<th>CSF-1R Mab</th>
<th>IC50 [μg/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mab2F11</td>
<td>0.08</td>
</tr>
<tr>
<td>Mab2F10</td>
<td>0.06</td>
</tr>
<tr>
<td>Mab2F11</td>
<td>0.03</td>
</tr>
<tr>
<td>Mab1G10</td>
<td>0.06</td>
</tr>
<tr>
<td>SC 2-A5</td>
<td>0.36</td>
</tr>
</tbody>
</table>

**Example 5**

**Table 5**

<table>
<thead>
<tr>
<th>CSF-1R Mab</th>
<th>0.07 μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mab2F11c11</td>
<td>0.07 μg/ml</td>
</tr>
<tr>
<td>Mab2F11d8</td>
<td>0.04 μg/ml</td>
</tr>
<tr>
<td>Mab2F11c7</td>
<td>0.09 μg/ml</td>
</tr>
</tbody>
</table>

**Example 4**

**Example 5**

In a separate test series humanized versions of Mab 2 F11, e.g. hMab2F11c11, hMab2F11d8, hMab2F11c7, hMab2F11d14, showed IC50 values of 0.07 μg/ml (hMab 2F11c11), 0.07 μg/ml (hMab2F11d8), 0.04 μg/ml (hMab 2F11c7) and 0.09 μg/ml (hMab2F11d14).
human CD163 (BD Bioscience Cat. No. 556018), PE labeled mouse anti human CD80 (BD Bioscience Cat. No. 557227) and Alexa 647 labeled mouse anti human MHC class II (Dako-Cat. No. M0775). The Alexa 647 label was conjugated to the antibody by using the Zenon Alexa 647 mouse IgG labeling kit (Invitrogen Cat. No. Z25008) After a 1-hour incubation on ice cells were washed twice with staining buffer, resuspended and measured at a FACS Canto II.

[0461] Exclusively M2 macrophage differentiation which is characterized by the expression of CD163, absence of CD80 and low MHC class II expression could be induced by addition of humanized anti-CSF-1R antibody hMab 2F11-e7. Furthermore, the M2 but not M1 macrophage survival is affected and could be analyzed by CellTiterGlo (CTG) analysis. Concentration dependent inhibition of the survival of macrophages by antibody treatment for 7 days is depicted in Fig. 1a. Expression of M1 and M2 macrophage markers assessed by flow cytometry is shown in Fig. 1b.

Example 6

CSF-1 Level Increase During CSF-1R Inhibition in Cynomolgus Monkey

[0462] Serum CSF-1 levels provide a pharmacodynamic marker of CSF-1R neutralizing activity of anti-human CSF-1R dimerization inhibitor hMab 2F11-e7. One male and one female cynomolgus monkey per dosage group (1 and 10 mg/kg) were intravenously administered anti-CSF1R antibody hMab 2F11-e7. Blood samples for analysis of CSF-1R levels were collected 1 week before treatment (pre-dose), 2, 24, 48, 72, 96, 168 hours post-dose and weekly for two additional weeks. CSF-1 levels were determined using a commercially available ELISA kit (Quantikine human M-CSF) according to the manufacturer’s instructions (R&D Systems, UK). Monkey CSF-1 level were determined by comparison with CSF-1 standard curve samples provided in the kit.

[0463] Administration of hMab 2F11-e7 induced a dramatic increase in CSF-1 by ~1000-fold, which depending on the dose administered lasted for 48 hr (1 mg/kg) or 15 days (10 mg/kg). Hence, a dimerization inhibitor for CSF-1R offers the advantage to not directly compete with the dramatically upregulated ligand for binding to the receptor in contrast to a ligand displacing antibody. (Results are shown in Fig. 2).

Example 7

Relationship Between M2 Subtype Tumor Associated Macrophages (TAMs) and T Cells—Rationale for Combining Anti-CSF-R1 Antibody and a T Cell Engaging Agents

[0464] To investigate the functional relationship between TAMs and T cells we isolated TAMs from the MC38 tumor and cocultured them with CD8+ T cells.

TAM Suppression Assay

[0465] TAMs were enriched from single cell suspensions of MC38 tumors after enzymatic digest using a two-step protocol: Single cells were stained with CD11b-FITC (clone M1/70) and positively enriched over MACS columns by anti-FITC beads (Miltenyi). Upon removal from the column, anti-FITC beads were detached using release buffer protocol as provided the manufacturer. Finally, TAM were isolated by adding anti-Ly6G and anti-Ly6C positive selection beads in order to remove granulocytic and monocytic cells from TAM preparations. Final cell purity was analyzed and was usually >90%. Subsequently, TAM were titrated in the indicated ratios to total CD3+ T cells labeled with CFSE in U-bottom plates coated with anti-CD3 and soluble anti-CD28 was added. Cell proliferation was determined from CFSElow cells using blank Sphero beads as previously described after 3 days of incubation (Hoves, S. et al. Monocyte-derived human macrophages mediate energy in allogeneic T cells and induce regulatory T cells. J. Immunol. 177, 2691-2698 (2006)). In the presence of TAMs, T cell expansion induced by activation of CD3 and CD28 was suppressed. (see Fig. 3).

Example 8

Inhibition of Tumor Growth Under Treatment with Anti-CSF-1R Monoclonal Antibody in Combination with PD-L1 Antibody in Subcutaneous Syngeneic MC38 Colon Carcinoma Model

[0466] Cells of the murine colorectal adenocarcinoma cell line MC38 (obtained from Beckman Research Institute of the City of Hope, Calif., USA) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, PAN Biotech) supplemented with 10% FCS and 2 mM L-glutamine at 37° C. in a water saturated atmosphere at 5% CO2. At the day of inoculation, MC38 tumor cells were harvested with PBS from culture flasks and transferred into culture medium, centrifuged, washed once and re-suspended in PBS. For injection of cells, the final titer was adjusted to 1x10^7 cells/ml. Subsequently 100 μl of this suspension (1x10^7 cells) were inoculated subcutaneously into 7-9 weeks old female C57BL/6N mice (obtained from Charles River, Sulzfeld, Germany). Treatment with control antibody (MOPC-21; Bio X Cell, West Lebanon), anti-murine CSF-1R mAb–mouse CSF1R antibody at a weekly dose of 30 mg/kg i.p. alone or in combination with a mouse crossreactive anti PD-L1 antibody (10 mg/kg i.p., 6x q3d) started after tumors were established and had reached an average size of 100 mm^3. Tumor volume was measured twice a week and animal weights were monitored in parallel.

[0467] In first experiment monotherapy with <mouse CSF1R>antibody did not inhibit primary tumor growth when compared to control antibody treatment (TGI: 0%, TCR: 1.07 CI: 0.80-1.43, median time to progression>700 mm^3; 21 days). Anti-PD-L1 monotherapy had an effect on MC38 primary tumor growth (TGI: 83%, TCR: 0.27 CI: 0.09-0.49, median time to progression>700 mm^3; 32 days). Addition of <mouse CSF1R> antibody to anti-PD-L1 therapy led to a slightly improved anti-tumor efficacy compared to anti-PD-L1 treatment alone (TGI: 85%, TCR: 0.28 CI: 0.09-0.51, median time to progression>700 mm^3; 57 days) (see table below).

<table>
<thead>
<tr>
<th>TABLE 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti tumor Efficacy of &lt;mouse anti-CSF1R&gt; antibody/&lt;anti-PD-L1&gt; antibody combination in the MC38 mouse C57B16J mouse model</td>
</tr>
<tr>
<td>Group</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Control (Mouse IgG)</td>
</tr>
<tr>
<td>&lt;mouse CSF1R&gt;</td>
</tr>
<tr>
<td>Anti-PD-L1</td>
</tr>
<tr>
<td>Anti-CSF1R + Anti-PD-L1</td>
</tr>
</tbody>
</table>

Mar. 12, 2015
TABLE 6-continued

<table>
<thead>
<tr>
<th>Group</th>
<th>TG1 (day 21)</th>
<th>TCR (day 12)</th>
<th>95% CI vs. group</th>
<th>Median time to progression</th>
<th>TV &gt; 700 mm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;anti-PD-L1&gt;</td>
<td>83%</td>
<td>0.27</td>
<td>(0.49-0.99)</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>&lt;mouse CSF1R&gt;&lt;anti-PD-L1&gt;</td>
<td>83%</td>
<td>0.28</td>
<td>(0.51-0.99)</td>
<td>37</td>
<td></td>
</tr>
</tbody>
</table>

[0468] Median time of progression > 700 mm² was 21 days for control (mouse IgG1) treated animals. Monotherapy with <mouse CSF1R> antibody did not inhibit primary tumor growth when compared to control antibody treatment (median time to progression > 700 mm²; 21 days). Anti-PD-L1 monotherapy had an effect on MC38 primary tumor growth (median time to progression > 700 mm²; 32 days). Addition of <mouse CSF1R> antibody to anti-PD-L1 therapy led to a slightly improved anti-tumor efficacy compared to PD-L1 treatment alone (median time to progression > 700 mm²; 37 days) (see table below and FIG. 4).

TABLE 7

<table>
<thead>
<tr>
<th>Group</th>
<th>Median time to progression</th>
<th>TV &gt; 700 mm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (Mouse IgG1)</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>&lt;mouse CSF1R&gt;</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>&lt;anti-PD-L1&gt;</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>&lt;mouse CSF1R&gt;&lt;anti-PD-L1&gt;</td>
<td>37</td>
<td></td>
</tr>
</tbody>
</table>

[0469] In analogous experiments, but starting treatment at different tumor sizes (e.g., starting treatment when the tumor has reached a volume above and below 100 mm³ (different groups are evaluated) and in a further experiment also using different anti PD-L1 antibodies described in table 2, the inhibition of tumor growth under treatment with anti-CSF-1R monoclonal antibody in combination with anti-PD-L1 antibody in subcutaneous syngeneic MC38 colon carcinoma model is evaluated.

Example 9

Inhibition of Tumor Growth Under Treatment with Anti-CSF-1R Monoclonal Antibody in Combination with PD-L1 Antibody in Subcutaneous Syngeneic CT26 WT Colon Carcinoma Model

[0470] Cells of the murine colorectal adenocarcinoma cell line CT26.WT tumor cells (obtained from ATCC) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, PAN Biotech) supplemented with 10% FCS and 2 mM L-glutamine at 37°C in a water saturated atmosphere at 5% CO2. At the day of inoculation, CT26.WT tumor cells were harvested with PBS from culture flasks and transferred into culture medium, centrifuged, washed once and re-suspended in PBS. For injection of cells, the final titer was adjusted to 1x10⁷ cells/ml. Subsequently 100 IA of this suspension (1x10⁶ cells) were inoculated subcutaneously into 11-13 weeks old female Balb/c mice (obtained from Charles River, Salzfeld, Germany). Treatment with control antibody (MOPC-21; Bio X Cell, West Lebanon), anti-murine CSF-1R mAb <mouse CSF1R> antibody at a weekly dose of 30 mg/kg i.p. alone or in combination with a mouse crossreactive anti PD-L1 antibody (10 mg/kg i.p., 6x q3d) started after tumors were established and had reached an average size of 150 mm³. While treatment in monotherapy groups started on day 9 after tumor cell inoculation, treatment in combination group was sequential (day 9: start of treatment with anti-murine CSF-1R mAb; day 11: start of treatment with anti PD-L1 antibody). Tumor volume was measured twice a week and animal weights were monitored in parallel. Results are shown in Figure

[0471] Median time to progression > 700 mm³ was 17 days for IgG control treatment group, 16 days for <mouse anti-CSF1R> antibody monotherapy group, 18 days for <anti-PD-L1> antibody monotherapy group and 18 days for <mouse anti-CSF1R><anti-PD-L1> antibody combination group.

[0472] While all animals in control or monotherapy groups needed to be terminated due to progressive tumor burden one animal of the <mouse anti-CSF1R><anti-PD-L1> antibody combination group experienced tumor shrinkage and remained tumor-free until study termination on day 79 after tumor inoculation.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 107
<210> SEQ ID NO 1
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQNR: 1

Asp Gln Arg Leu Tyr Phe Asp Val
1 5
<table>
<thead>
<tr>
<th>Val</th>
<th>Ile</th>
<th>Trp</th>
<th>Thr</th>
<th>Asp</th>
<th>Gly</th>
<th>Thr</th>
<th>Asn</th>
<th>Tyr</th>
<th>Asn</th>
<th>Ser</th>
<th>Pro</th>
<th>Phe</th>
<th>Met</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**<400> SEQUENCE: 2**

Val Ile Trp Thr Asp Gly Thr Asn Tyr Asn Ser Pro Phe Met Ser

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**<210> SEQ ID NO 3**

**LENGTH: 5**

**TYPE: PRT**

**ORGANISM: Mus musculus**

**<400> SEQUENCE: 3**

Thr Tyr Asp Ile Ser

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**<210> SEQ ID NO 4**

**LENGTH: 8**

**TYPE: PRT**

**ORGANISM: Mus musculus**

**<400> SEQUENCE: 4**

Gly Gln Ser Phe Ser Tyr Pro Thr

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**<210> SEQ ID NO 5**

**LENGTH: 7**

**TYPE: PRT**

**ORGANISM: Mus musculus**

**<400> SEQUENCE: 5**

Gly Ala Ser Asn Arg Tyr Thr

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**<210> SEQ ID NO 6**

**LENGTH: 11**

**TYPE: PRT**

**ORGANISM: Mus musculus**

**<400> SEQUENCE: 6**

Lys Ala Ser Glu Asp Val Asn Thr Tyr Val Ser

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

**<210> SEQ ID NO 7**

**LENGTH: 116**

**TYPE: PRT**

**ORGANISM: Mus musculus**

**<400> SEQUENCE: 7**

Gln Val Gin Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gin

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Asp Ile Ser Trp Ile Arg Gin Ser Pro Gly Lys Gly Leu Glu Trp Leu

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Gly Val Ile Thr Thr Asp Gly Gly Thr Asn Tyr Asn Ser Pro Phe Met

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Ser Arg Leu Ser Ile Arg Lys Asp Asn Ser Lys Ser Gin Val Phe Leu

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Lys Met Asn Arg Leu Gin Thr Asp Thr Ala Ile Tyr Tyr Cys Val

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |

Arg Asp Gin Arg Leu Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val
Thr Val Ser Ser
115

<210> SEQ ID NO: 8
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 8
Asn  Ile  Val  Met  Thr  Gln  Ser  Pro  Lys  Ser  Met  Ser  Met  Ser  Val  Gly
1   5   10   15
Glu  Arg  Val  Thr  Leu  Asn  Cys  Lys  Ala  Ser  Glu  Asp  Val  Asn  Thr  Tyr
20  25  30
Val  Ser  Trp  Tyr  Gln  Gln  Gln  Pro  Glu  Gln  Ser  Pro  Lys  Leu  Leu  Ile
35  40  45
Tyr  Gly  Ala  Ser  Asn  Arg  Tyr  Thr  Gly  Val  Pro  Asp  Arg  Phe  Thr  Gly
50  55  60
Gly  Gly  Ser  Thr  Thr  Asp  Phe  Thr  Leu  Thr  Ile  Ser  Ser  Val  Glu  Ala
65  70  75  80
Glu  Asp  Leu  Ala  Asp  Tyr  Phe  Cys  Gly  Glu  Ser  Phe  Ser  Tyr  Pro  Thr
85  90
Phe  Gly  Thr  Gly  Thr  Lys  Leu  Glu  Ile  Lys
100  105

<210> SEQ ID NO: 9
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 9
Asp  Pro  Arg  Leu  Tyr  Phe  Asp
1   5

<210> SEQ ID NO: 10
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 10
Val  Ile  Trp  Thr  Gly  Gly  Thr  Asn  Tyr  Asn  Ser  Gly  Phe  Met  Ser
1   5   10   15

<210> SEQ ID NO: 11
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 11
Ser  Phe  Asp  Ile  Ser
1   5

<210> SEQ ID NO: 12
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 12
Gly  Gln  Thr  Phe  Ser  Tyr  Pro  Thr
-continued

1  5

<210> SEQ ID NO 13
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 13

Gly Ala Ser Asn Arg Tyr Thr
1  5

<210> SEQ ID NO 14
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 14

Lys Ala Ser Glu Asp Val Val Thr Tyr Val Ser
1  5 10

<210> SEQ ID NO 15
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 15

Gln Val Glu Gin Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Lys
1  5 10 15

Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Ser Ser Leu Asp Ser Ser
20 25 30

Asp Ile Ser Trp Ile Arg Gin Ser Pro Gly Lys Gly Leu Gin Trp Leu
35 40 45

Gly Val Ile Thr Gly Lys Gly Thr Asn Tyr Asn Ser Gly Phe Met
50 55 60

Ser Arg Leu Arg Ile Thr Lys Asp Ser Ser Gin Val Leu Leu
65 70 75 80

Lys Met Asn Ser Leu Gin Ser Asp Thr Ala Ile Tyr Tyr Cys Val
85 90 95

Arg Asp Pro Arg Leu Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> SEQ ID NO 16
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 16

Asn Ile Val Met Thr Gin Ser Pro Lys Ser Met Ser Met Ser Val Gly
1  5 10 15

Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asp Val Thr Tyr
20 25 30

Val Ser Trp Tyr Gin Gin Lys Gin Pro Asp Gin Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
| Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr | Ile Ser Ser Val Glu Ala |
|  65  |  70  |  75  |  80  |
| Glu Asp Leu Ala Asp Tyr Tyr Cys Gly Gln Thr Phe Ser Tyr Pro Thr |
|  85  |  90  |  95  |
| Phe Gly Thr Gly Thr Lys Leu Glu Ile Lys |
| 100  | 105  |

**SEQ ID NO 17**
**LENGTH:** 8  
**TYPE:** PRT  
**ORGANISM:** Artificial  
**FEATURE:**  
**OTHER INFORMATION:** heavy chain CDR3, mAb 2F11-c11  

**SEQUENCE:** 17

Asp Gln Arg Leu Tyr Phe Asp Val  
1  5

**SEQ ID NO 18**
**LENGTH:** 16  
**TYPE:** PRT  
**ORGANISM:** Artificial  
**FEATURE:**  
**OTHER INFORMATION:** heavy chain CDR2, mAb 2F11-c11  

**SEQUENCE:** 18

Val Ile Trp Thr Asp Gly Thr Asn Tyr Asn Ser Pro Phe Met Ser  
1  5  10  15

**SEQ ID NO 19**
**LENGTH:** 9  
**TYPE:** PRT  
**ORGANISM:** Artificial  
**FEATURE:**  
**OTHER INFORMATION:** heavy chain CDR1, mAb 2F11-c11  

**SEQUENCE:** 19

Thr Tyr Asp Ile Ser  
1  5

**SEQ ID NO 20**
**LENGTH:** 8  
**TYPE:** PRT  
**ORGANISM:** Artificial  
**FEATURE:**  
**OTHER INFORMATION:** light chain CDR3, mAb 2F11-c11  

**SEQUENCE:** 20

Gly Gln Ser Phe Ser Tyr Pro Thr  
1  5

**SEQ ID NO 21**
**LENGTH:** 7  
**TYPE:** PRT  
**ORGANISM:** Artificial  
**FEATURE:**  
**OTHER INFORMATION:** light chain CDR2, mAb 2F11-c11  

**SEQUENCE:** 21

Gly Ala Ser Asn Arg Tyr Thr  
1  5

**SEQ ID NO 22**
Arg Ala Ser Glu Asp Val Asn Thr Tyr Val Ser

Gln Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Pro Gly Ser

Asp Ile Ser Trp Ile Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

Gly Val Ile Thr Asp Gly Gly Thr Asn Tyr Ser Pro Phe Met

Ser Arg Val Thr Ile Thr Lys Asp Glu Ser Thr Ser Thr Ala Tyr Met

Glu Leu Ser Ser Leu Arg Ser Glu Thr Ala Val Tyr Cys Val

Arg Asp Gin Arg Leu Tyr Phe Asp Val Trp Gly Gin Gly Thr Thr Val

Thr Val Ser Ser

Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Val Asn Thr Tyr

Val Ser Trp Tyr Gin Gln Gin Gly Lys Ala Pro Gly Lys Leu Leu Ile

Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gin Ser Phe Ser Tyr Pro Thr

Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys
Amp Glu Arg Leu Tyr Phe Asp Val
1  5

Val Ile Trp Thr Asp Gly Ala Asn Tyr Ala Glu Phe Gin Gly
1  5 10 15

Thr Tyr Asp Ile Ser
1  5

Gly Gin Ser Phe Ser Tyr Pro Thr
1  5

Gly Ala Ser Asn Arg Tyr Thr
1  5

Lys Ala Ser Glu Asp Val Asn Thr Tyr Val Ser
<210> SEQ ID NO 31
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain variable domain, mAb 2F11-d8

<400> SEQUENCE: 31
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30
Amp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Val Ile Trp Thr Asp Gly Gly Ala Asn Tyr Ala Gly Lys Phe Gln
50 55 60
Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Ser Ala Tyr Met
65 70 75 80
Glu Leu Ser Ser Leu Arg Ser Glu Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Asp Gln Arg Leu Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val
100 105 110
Thr Val Ser Ser
115

<210> SEQ ID NO 32
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain variable domain, mAb 2F11-d9

<400> SEQUENCE: 32
Amp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Amp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp Val Asn Thr Tyr
20 25 30
Val Ser Trp Tyr Gin Gln Gin Pro Gly Lys Ala Pro Gly Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Glu Ser Phe Ser Tyr Pro Thr
89 90
Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 33
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR3, mAb 2F11-e7

<400> SEQUENCE: 33
Asp Gln Arg Leu Tyr Phe Asp Val
1  6

<210> SEQ ID NO 34
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR2, mAb 2F11-e7
<400> SEQUENCE: 34

Val Ile Trp Thr Asp Gly Gly Thr Asn Tyr Ala Gln Lys Leu Gln Gly
1  5  10  15

<210> SEQ ID NO 35
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR1, mAb 2F11-e7
<400> SEQUENCE: 35

Ser Tyr Asp Ile Ser
1  5

<210> SEQ ID NO 36
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain CDR1, mAb 2F11-e7
<400> SEQUENCE: 36

Gln Gln Ser Phe Ser Tyr Pro Thr
1  5

<210> SEQ ID NO 37
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain CDR2, mAb 2F11-e7
<400> SEQUENCE: 37

 Ala Ala Ser Asn Arg Tyr Thr
1  5

<210> SEQ ID NO 38
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain CDR1, mAb 2F11-e7
<400> SEQUENCE: 38

Arg Ala Ser Glu Asp Val Asn Thr Tyr Val Ser
1  5  10

<210> SEQ ID NO 39
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain variable domain, mAb 2F11-e7
<400> SEQUENCE: 39
Gln Val Gin Leu Val Gin Ser Gly Ala Gin Val Lys Gin Pro Gin Ala
1  5  10  15
Ser Val Lys Val Ser Cys Gin Ala Ser Gin Lys Tyr Thr Phe Thr Ser Tyr
20 25 30
Asp Ile Ser Thr Val Gin Ala Pro Gin Gin Leu Gin Trp Met
35 40 45
Gly Val Ile Thr Gin Thr Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
50 55 60
Gly Gin Gin Thr Gin Gin Gin Ser Gin Ser Thr Gin Gin Gin Gin Gin Gin
65 70 75 80
Glu Gin Gin Gin Gin Ser Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
85 90 95
Arg Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
100 105 110
Thr Val Ser Ser
115

<210> SEQ ID NO 40
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain variable domain, mAb 2F11-e7

<400> SEQUENCE: 40
Asp Ile Gin Met Thr Gin Ser Gin Ser Ser Leu Ser Ala Gin Val Gly
1  5  10  16
Asp Gin Gin Thr Gin Thr Cys Gin Ala Ser Gin Gin Gin Gin Gin Gin Gin
20 25 30
Val Ser Thr Tyr Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
35 40 45
Tyr Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
50 55 60
Ser Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
65 70 75 80
Glu Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
85 90 95
Phe Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
100 105 109

<210> SEQ ID NO 41
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR3, mAb 2F11-f12

<400> SEQUENCE: 41
Asp Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin
1  5

<210> SEQ ID NO 42
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial
Val Ile Trp Thr Asp Gly Thr Asn Tyr Asn Ser Pro Phe Met Ser
1 5 10 15

Thr Tyr Asp Ile Ser
1 5

Gly Gln Ser Phe Ser Tyr Pro Thr
1 5

Gly Ala Ser Ser Leu Gln Ser
1 5

Arg Ala Ser Glu Asp Val Asn Thr Tyr Val Ser
1 5 10

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30
-continued

| Amp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met |
|---------------------------------|---|---|---|---|---|
| Gly Val Ile Trp Thr Asp Gly Gly Thr Asn Tyr Asn Ser Pro Phe Met |
| Ser Arg Val Thr Ile Thr Lys Asp Glu Ser Thr Ser Thr Ala Tyr Met |
| Glu Leu Ser Ser Arg Ser Glu Asp Thr Ala Val Tyr Cys Val |
| Arg Asp Glu Arg Leu Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val |
| Thr Val Ser Ser |

115

<210> SEQ ID NO 48
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain variable domain, mMab 2F11-f12

<400> SEQUENCE: 48

Amp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ala Ser Val Gly
1 5 10 15

Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asp Val Asn Thr Tyr
20 25 30

Val Ser Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Ser Leu Gin Ser Gin Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gin Gin Thr Gin Thr Gin Thr Leu Thr Ile Ser Ser Leu Gin Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Cys Gly Gin Ser Phe Ser Tyr Pro Thr
85 90 95

Phe Gin Gin Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 49
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR3, mMab 2F11-g1

<400> SEQUENCE: 49

Amp Gin Arg Leu Tyr Phe Asp Val
1 5

<210> SEQ ID NO 50
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: heavy chain CDR2, mMab 2F11-g1

<400> SEQUENCE: 50

Val Ile Trp Thr Asp Gly Gly Thr Asn Tyr Asn Ser Pro Leu Lys Ser
1 5 10 15
Thr Tyr Asp Ile Ser
1 5

Gly Gln Ser Phe Ser Tyr Pro Thr
1 5

Gly Ala Ser Ser Arg Ala Thr
1 5

Arg Ala Ser Glu Asp Val Asn Thr Tyr Leu Ala
1 5 10

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30

Amp Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Trp Thr Asp Gly Gly Thr Asn Tyr Asn Ser Pro Leu Lys
50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Ser
65 70 75 80
-continued

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 98

Arg Asp Gln Arg Leu Tyr Phe Asp Val Trp Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> SEQ ID NO 56
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: light chain variable domain, HMab 2F11-g1

<400> SEQUENCE: 56

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asp Val Asn Thr Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Gly Pro
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gly Gin Ser Phe Ser Tyr Pro Thr
85 90 95

Phe Gly Gin Gly Thr Leu Leu Glu Ile Lys
100 105

<210> SEQ ID NO 57
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 57

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30

Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn Ala Leu Gin
35 40 45

Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Ser Lys Asp Ser
50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser
85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> SEQ ID NO 58
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58
 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
   1    5    10   15
Ser Thr Ser Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
  20   25     30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
  35    40
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Thr Ser
  45     50     55     60
Leu Ser Ser Val Thr Val Thr Val Ser Leu Gly Thr Gin Thr
  65    70    75    80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
  95     99    100     105
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100    105     110
Pro Ala Pro Glu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115    120     125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130    135    140
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145    150    155    160
Tyr Val Asp Gly Glu Val Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165    170     175
Glu Gin Tyr Asn Ser Thr Tyr Arg Val Ser Val Leu Thr Val Leu
 180    185     190
His Gin Asp Thr Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195    200     205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210    215    220
Gln Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 225    230    235    240
Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245    250     255
Pro Ser Asp Ile Ala Val Glu Trp Gin Ser Asn Gly Gin Pro Glu Asn
 260    265     270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275    280     285
Leu Tyr Ser Lys Thr Thr Asp Lys Ser Asp Gin Gin Gly Asn
 290    295     300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305    310    315     320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325    330

<210> SEQ ID NO: 59
<211> LENGTH: 330
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
  <223> OTHER INFORMATION: human heavy chain constant region derived from
  IgGl mutated on L234A and L235A
<400> SEQUENCE: 59
   Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1          5          10         15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
    20         25        30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
    35         40        45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50         55        60
Leu Ser Ser Val Thr Val Thr Val Pro Ser Ser Leu Gly Thr Gin Thr
    65         70        75        80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
    85         90        95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
   100        105       110
Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
   115        120       125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
   130        135       140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
   145        150       155       160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Pro Arg Glu
   165        170       175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
   180        185       190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Leu Val Ser Asn
   195        200       205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
   210        215       220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
   225        230       235       240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
   245        250       255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
   260        265       270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
   275        280       285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn
   290        295       300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
   305        310       315       320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
   325        330

<210> SEQ ID NO 60
<211> LENGTH: 327
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 60
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
    1          5          10         15
Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
    20         25        30
<table>
<thead>
<tr>
<th></th>
<th>Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Gly Leu Tyr Ser</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>Leu Ser Ser Val Thr Val Pro Ser Ser Leu Gly Thr Lys Thr</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>85</td>
<td>Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>100</td>
<td>Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro</td>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>115</td>
<td>Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys</td>
<td>120</td>
<td>125</td>
</tr>
<tr>
<td>130</td>
<td>Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val</td>
<td>135</td>
<td>140</td>
</tr>
<tr>
<td>145</td>
<td>Asp Val Ser Gin Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp</td>
<td>150</td>
<td>155</td>
</tr>
<tr>
<td>165</td>
<td>Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Gin Phe</td>
<td>170</td>
<td>175</td>
</tr>
<tr>
<td>180</td>
<td>Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp</td>
<td>185</td>
<td>190</td>
</tr>
<tr>
<td>195</td>
<td>Trp Leu Asn Gly Lys Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu</td>
<td>200</td>
<td>205</td>
</tr>
<tr>
<td>210</td>
<td>Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg</td>
<td>215</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Gin Glu Gin Met Thr Lys</td>
<td>225</td>
<td>230</td>
</tr>
<tr>
<td>245</td>
<td>Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp</td>
<td>250</td>
<td>255</td>
</tr>
<tr>
<td>260</td>
<td>Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys</td>
<td>265</td>
<td>270</td>
</tr>
<tr>
<td>270</td>
<td>Thr Thr Pro Pro Val Leu Asp Ser Gin Gly Ser Phe Leu Tyr Ser</td>
<td>275</td>
<td>280</td>
</tr>
<tr>
<td>290</td>
<td>Arg Leu Thr Val Asp Lys Ser Arg Trp Gin Glu Gin Asn Val Phe Ser</td>
<td>295</td>
<td>300</td>
</tr>
<tr>
<td>305</td>
<td>Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser</td>
<td>310</td>
<td>315</td>
</tr>
<tr>
<td>325</td>
<td>Leu Ser Leu Ser Leu Gly Lys</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 61
<211> LENGTH: 327
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: human heavy chain constant region derived from IgG4 mutated onS228P

<400> SEQUENCE: 61

<table>
<thead>
<tr>
<th></th>
<th>Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5 15</td>
</tr>
<tr>
<td></td>
<td>Ser Thr Ser Glu Ser Thr Ala Leu Gly Cys Leu Val Lys Asp Tyr</td>
</tr>
<tr>
<td>20</td>
<td>25 30</td>
</tr>
<tr>
<td></td>
<td>Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser</td>
</tr>
<tr>
<td>35</td>
<td>40 45</td>
</tr>
</tbody>
</table>
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50  55  60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65  70  75  80
Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85  90  95
Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro
100 105 110
Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140
Asp Val Ser Gin Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp
145 150 155 160
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Gin Phe Gin
165 170 175
Asn Ser Thr Tyr Arg Val Val Ser Val Ser Val Lys Gin Lys Gin Asp
180 185 190
Trp Leu Asn Gly Lys Tyr Lys Cys Lys Val Ser Lys Lys Gly Leu
195 200 205
Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gin Lys Pro Arg
210 215 220
Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Gin Glu Gin Met Thr Lys
225 230 235 240
Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255
Ile Ala Val Glu Trp Glu Ser Asn Gin Glu Pro Gin Asn Tyr Lys
260 265 270
Thr Thr Pro Pro Val Leu Asp Ser Asp Gin Ser Phe Leu Tyr Ser
275 280 285
Arg Leu Thr Val Asp Lys Ser Arg Trp Gin Glu Gin Val Phe Ser
290 295 300
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Glu Lys Ser
305 310 315 320
Leu Ser Leu Ser Ser Leu Gly Lys
325

<210> SEQ ID NO 62
<211> LENGTH: 972
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 62
Met Gly Pro Gly Val Leu Leu Leu Leu Val Ala Thr Ala Trp His
1  5  10  15
Gly Gin Gly Ile Pro Val Ile Glu Pro Ser Val Pro Glu Leu Val Val
20  25  30
Lys Pro Gly Ala Thr Val Thr Leu Arg Cys Val Gly Asn Gin Ser Val
35  40  45
Glu Trp Asp Gly Pro Pro Ser Pro Pro His Thr Thr Leu Tyr Ser Asp Gly
50  55  60
Ser Ser Ser Ile Leu Ser Thr Asn Ala Thr Thr Gin Asn Thr Gin
<table>
<thead>
<tr>
<th></th>
<th>65</th>
<th>70</th>
<th>75</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thr Tyr Arg Cys Thr Glu Pro Gly Asp Pro Leu Gly Ser Ala Ala</td>
<td>85</td>
<td>90</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Ile His Leu Tyr Val Lys Asp Pro Ala Arg Pro Trp Asn Val Leu Ala</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Gln Glu Val Val Phe Glu Asp Gln Asp Ala Leu Leu Pro Cys Leu</td>
<td>115</td>
<td>120</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Leu Thr Asp Pro Val Leu Glu Ala Gly Val Ser Leu Val Arg Val Arg</td>
<td>130</td>
<td>135</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Gly Arg Pro Leu Met Arg His Thr Asn Tyr Ser Phe Ser Pro Trp His</td>
<td>145</td>
<td>150</td>
<td>155</td>
<td>160</td>
</tr>
<tr>
<td>Gly Phe Thr Ile His Arg Ala Lys Phe Ile Gln Ser Gln Asp Tyr Gin</td>
<td>165</td>
<td>170</td>
<td>175</td>
<td></td>
</tr>
<tr>
<td>Cys Ser Ala Leu Met Gly Gln Arg Lys Val Met Ser Ile Ser Ile Arg</td>
<td>180</td>
<td>185</td>
<td>190</td>
<td></td>
</tr>
<tr>
<td>Leu Lys Val Gin Lys Val Ile Pro Gly Pro Pro Ala Leu Thr Leu Val</td>
<td>195</td>
<td>200</td>
<td>205</td>
<td></td>
</tr>
<tr>
<td>Pro Ala Glu Leu Val Arg Ile Arg Gly Glu Ala Ala Gin Ile Val Cys</td>
<td>210</td>
<td>215</td>
<td>220</td>
<td></td>
</tr>
<tr>
<td>Ser Ala Ser Val Asp Val Asn Phe Asp Val Phe Leu Gin His Asn</td>
<td>225</td>
<td>230</td>
<td>235</td>
<td>240</td>
</tr>
<tr>
<td>Asn Thr Lys Leu Ala Ile Pro Gin Gin Ser Asp Phe His Asn Gin Arg</td>
<td>245</td>
<td>250</td>
<td>255</td>
<td></td>
</tr>
<tr>
<td>Tyr Gin Lys Val Leu Thr Leu Asn Leu Asp Gin Val Asp Phe Gin His</td>
<td>260</td>
<td>265</td>
<td>270</td>
<td></td>
</tr>
<tr>
<td>Ala Gin Tyr Ser Cys Val Ala Ser Asn Val Gin Gly Lys His Ser</td>
<td>275</td>
<td>280</td>
<td>285</td>
<td></td>
</tr>
<tr>
<td>Thr Ser Met Phe Phe Arg Val Val Glu Ser Ala Tyr Leu Asn Leu Ser</td>
<td>290</td>
<td>295</td>
<td>300</td>
<td></td>
</tr>
<tr>
<td>Ser Gin Asn Leu Ile Gin Glu Val Thr Val Gly Glu Gly Leu Asn</td>
<td>305</td>
<td>310</td>
<td>315</td>
<td>320</td>
</tr>
<tr>
<td>Leu Lys Val Met Val Glu Ala Tyr Pro Gly Leu Gin Gin Phe Asn Trp</td>
<td>325</td>
<td>330</td>
<td>335</td>
<td></td>
</tr>
<tr>
<td>Thr Tyr Leu Gly Pro Phe Ser Asp His Gin Pro Glu Pro Lys Leu Ala</td>
<td>340</td>
<td>345</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Asn Ala Thr Thr Lys Arg Thr Tyr Arg His Thr Phe Thr Leu Ser Leu</td>
<td>355</td>
<td>360</td>
<td>365</td>
<td></td>
</tr>
<tr>
<td>Pro Arg Leu Lys Pro Ser Glu Ala Gly Arg Tyr Ser Phe Leu Ala Arg</td>
<td>370</td>
<td>375</td>
<td>380</td>
<td></td>
</tr>
<tr>
<td>Asn Pro Gly Gin Trp Arg Ala Leu Thr Phe Glu Leu Thr Leu Arg Tyr</td>
<td>385</td>
<td>390</td>
<td>395</td>
<td>400</td>
</tr>
<tr>
<td>Pro Pro Glu Val Ser Val Ile Trp Thr Phe Ile Asn Gin Ser Gly Thr</td>
<td>405</td>
<td>410</td>
<td>415</td>
<td></td>
</tr>
<tr>
<td>Leu Leu Cys Ala Ala Ser Gly Tyr Pro Gin Pro Asn Val Thr Trp Leu</td>
<td>420</td>
<td>425</td>
<td>430</td>
<td></td>
</tr>
<tr>
<td>Gln Cys Ser Gly His Thr Asp Arg Cys Asp Glu Ala Gin Val Leu Gin</td>
<td>445</td>
<td>445</td>
<td>445</td>
<td></td>
</tr>
<tr>
<td>Val Trp Asp Asp Pro Tyr Pro Glu Val Leu Ser Gin Glu Pro Phe His</td>
<td>450</td>
<td>455</td>
<td>460</td>
<td></td>
</tr>
<tr>
<td>Lys Val Thr Val Gin Ser Leu Leu Thr Val Glu Thr Leu Glu His Asn</td>
<td>465</td>
<td>470</td>
<td>475</td>
<td>480</td>
</tr>
</tbody>
</table>
-continued

<table>
<thead>
<tr>
<th>Gly</th>
<th>Pro</th>
<th>Val</th>
<th>Leu</th>
<th>Leu</th>
<th>Leu</th>
<th>Val</th>
<th>Ala</th>
<th>Thr</th>
<th>Ala</th>
<th>Trp</th>
<th>His</th>
</tr>
</thead>
<tbody>
<tr>
<td>885</td>
<td>890</td>
<td>895</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro</td>
<td>Thr</td>
<td>His</td>
<td>Arg</td>
<td>Pro</td>
<td>Thr</td>
<td>Phe</td>
<td>Gln</td>
<td>Gln</td>
<td>Ile</td>
<td>Cys</td>
<td>Ser</td>
</tr>
<tr>
<td>900</td>
<td>905</td>
<td>910</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Ala</td>
<td>Gln</td>
<td>Glu</td>
<td>Asp</td>
<td>Arg</td>
<td>Arg</td>
<td>Arg</td>
<td>Gly</td>
<td>Ser</td>
<td>Ser</td>
<td>Tyr</td>
</tr>
<tr>
<td>915</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>920</td>
<td>925</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Ser</td>
<td>Arg</td>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
<td>Ser</td>
<td>Ser</td>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td>930</td>
<td>935</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu</td>
<td>Ser</td>
<td>Ser</td>
<td>Glu</td>
<td>His</td>
<td>Leu</td>
<td>Thr</td>
<td>Cys</td>
<td>Cys</td>
<td>Gly</td>
<td>Asp</td>
<td>Ile</td>
</tr>
<tr>
<td>945</td>
<td>950</td>
<td>955</td>
<td>960</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Pro</td>
<td>Leu</td>
<td>Gln</td>
<td>Pro</td>
<td>Arg</td>
<td>Arg</td>
<td>Tyr</td>
<td>Gln</td>
<td>Phe</td>
<td>Cys</td>
<td></td>
</tr>
<tr>
<td>965</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 63
<211> LENGTH: 972
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: mutant CSF-1R L301S Y969F

<400> SEQUENCE: 63

Met | Gly | Pro | Gly | Val | Leu | Leu | Leu | Leu | Val | Ala | Thr | Ala | Trp | His |
| 1  | 5   | 10  |     |     |     |     |     |     |     |     |     |     |     |     |
Gly | Gln | Gly | Ile | Pro | Val | Ile | Glu | Pro | Ser | Val | Pro | Leu | Val | Val |
| 20 | 25  |     |     | 30  |     |     |     |     |     |     |     |     |     |     |
Lys | Pro | Gln | Gly | Ala | Thr | Val | Thr | Leu | Arg | Cys | Val | Gln | Gly | Ser | Val |
| 35 | 40  |     |     |     |     |     |     |     |     |     |     |     |     |     |
Glu | Trp | Asp | Gly | Pro | Ser | Pro | Ser | His | Trp | Thr | Leu | Tyr | Ser | Asp | Gly |
| 50 | 55  | 60  |     |     |     |     |     |     |     |     |     |     |     |     |
Ser | Ser | Ser | Gly | Leu | Ser | Thr | Asn | Arg | Ala | Thr | Phe | Gln | Arg | Ser | Gly |
| 65 | 70  | 75  | 80  |     |     |     |     |     |     |     |     |     |     |     |
Thr | Tyr | Arg | Cys | Thr | Gly | Pro | Gly | Asp | Pro | Leu | Gly | Ser | Ala | Ala |
| 85 | 90  |     | 95  |     |     |     |     |     |     |     |     |     |     |     |
Ile | His | Leu | Tyr | Val | Lys | Asp | Pro | Ala | Arg | Pro | Trp | Ala | Val | Leu |
| 100 | 105 |     |     | 110 |     |     |     |     |     |     |     |     |     |     |
Gln | Gly | Val | Val | Phe | Glu | Asp | Gly | Ala | Leu | Pro | Cys | Leu |     |     |
| 115 |     | 120 | 125 |     |     |     |     |     |     |     |     |     |     |     |
Leu | Thr | Asp | Pro | Val | Gly | Ala | Gly | Val | Ser | Leu | Val | Arg | Val | Arg |
| 130 | 135 | 140 |     |     |     |     |     |     |     |     |     |     |     |     |
Gly | Arg | Pro | Leu | Met | Arg | His | Thr | Asn | Tyr | Ser | Phe | Ser | Pro | Trp | His |
| 145 | 150 | 155 | 160 |     |     |     |     |     |     |     |     |     |     |     |     |
Gly | Phe | Thr | Ile | His | Arg | Ala | Gly | Phe | Ile | Gln | Ser | Gly | Asp | Tyr | Gln |
| 165 | 170 | 175 |     |     |     |     |     |     |     |     |     |     |     |     |     |
Cys | Ser | Ala | Leu | Met | Gly | Arg | Lys | Val | Met | Ser | Ile | Ser | Ile | Arg |
| 180 | 185 | 190 |     |     |     |     |     |     |     |     |     |     |     |     |     |
Leu | Lys | Val | Gln | Lys | Val | Ile | Pro | Gly | Pro | Pro | Ala | Leu | Thr | Leu | Val |
| 195 |     | 200 |     |     |     |     |     |     |     |     |     |     |     |     |     |
Pro | Ala | Glu | Leu | Val | Arg | Arg | Gly | Glu | Ala | Glu | Ile | Val | Cys |     |
| 210 | 215 | 220 |     |     |     |     |     |     |     |     |     |     |     |     |     |
Ser | Ala | Ser | Ser | Val | Arg | Ala | Gly | Phe | Arg | Ser | Val | Phe | Leu | Gln | His |
| 225 | 230 | 235 | 240 |     |     |     |     |     |     |     |     |     |     |     |     |
Amm | Thr | Lys | Ala | Ile | Pro | Gln | Gln | Ser | Asp | Phe | His | Arg |     |     |     |
Tyr Gln Lys Val Leu Thr Leu Asn Leu Asp Gln Val Asp Phe Gln His 260 265 270
Ala Gly Asn Tyr Ser Cys Val Ala Ser Asn Val Gln Gly Lys His Ser 275 280 285
Thr Ser Met Phe Phe Arg Val Val Ser Ala Tyr Ser Asn Leu Ser 290 295 300
Ser Gln Gin Asn Leu Ile Gin Glu Val Thr Val Gly Gly Gly Leu Asn 305 310 315 320
Leu Lys Val Met Val Glu Ala Tyr Pro Gly Leu Gln Gly Phe Asn Trp 325 330 335
Thr Tyr Leu Gly Pro Phe Ser Asp His Gin Pro Glu Pro Lys Leu Ala 340 345 350
Asn Ala Thr Thr Thr Asn Thr Arg His Thr Phe Thr Leu Ser Leu 355 360 365
Pro Arg Leu Lys Pro Ser Gln Ala Gly Arg Tyr Ser Phe Leu Ala Arg 370 375 380
Asn Pro Gly Gly Trp Arg Ala Leu Thr Phe Glu Leu Thr Leu Arg Tyr 395 390 395 400
Pro Pro Glu Val Ser Val Ile Trp Thr Phe Ile Asn Gly Ser Gly Thr 405 410 415
Leu Leu Cys Ala Ala Ser Gly Tyr Pro Gin Pro Asn Val Thr Trp Leu 420 425 430
Gln Cys Ser Gly His Thr Asp Arg Cys Asp Gln Val Gin Val Leu Gin 435 440 445
Val Trp Asp Asp Pro Tyr Pro Glu Val Leu Ser Gin Glu Pro Phe His 450 455 460
Lys Val Thr Val Gin Ser Leu Leu Thr Val Glu Thr Leu Glu His Asn 465 470 475 480
Gln Thr Tyr Glu Cys Arg Ala His Asn Ser Val Gly Ser Gly Ser Trp 485 490 495
Ala Phe Ile Pro Ile Ser Ser Ala Gly Ala His Thr His Pro Pro Asp Glu 500 505 510
Phe Leu Phe Thr Pro Val Val Ala Cys Met Ser Ile Met Ala Leu 515 520 525
Leu Leu Leu Leu Leu Leu Leu Leu Leu Tyr Lys Tyr Lys Gln Lys Pro 530 535 540
Lys Tyr Glu Gin Arg Trp Lys Ile Glu Ser Tyr Glu Gly Asn Ser 545 550 555 560
Thr Thr Phe Ile Asp Pro Thr Gin Leu Pro Tyr Asn Glu Lys Trp Glu 565 570 575
Phe Pro Arg Asn Asn Leu Gin Phe Gly Lys Thr Leu Gly Ala Gly Ala 580 585 590
Phe Gly Lys Val Val Glu Ala Thr Ala Phe Gly Leu Gly Lys Glu Asp 595 600 605
Ala Val Leu Lys Val Ala Val Lys Met Leu Lys Ser Thr Ala His Ala 610 615 620
Asp Glu Lys Glu Ala Leu Met Ser Glu Leu Ile Met Ser His Leu 625 630 635 640
Gly Gin His Gin Asn Ile Val Asn Leu Gly Ala Cys Thr His Gly 645 650 655
Gly Pro Val Leu Val Ile Thr Glu Tyr Cys Tyr Gly Asp Leu Leu
Aam Phe Leu Arg Arg Lys Ala Glu Ala Met Leu Gly Pro Ser Leu Ser 660 665 670
Pro Gly Gln Asp Pro Glu Gly Val Asp Tyr Lys Asn Ile His Leu 675 680 685
Glu Lys Tyr Val Arg Arg Asp Ser Gly Phe Ser Ser Gln Gly Val 690 695 700
Asp Thr Tyr Val Glu Met Arg Pro Val Ser Thr Ser Ser Asp Ser 705 710 715 720
Phe Ser Glu Gin Asp Leu Gin Glu Asp Gly Arg Pro Leu Glu Leu 725 730 735 740
Arg Asp Leu Leu His Phe Ser Ser Gin Val Ala Gin Gly Met Ala Phe 745 750 755
Leu Ala Ser Lys Aam Cys Ile His Arg Asp Val Ala Ala Arg Asn Val 760 765 770 775
Leu Leu Thr Asn Gln His Val Ala Lys Ile Glu Asp Phe Gly Leu Ala 780 785 790 795
Arg Asp Ile Met Aam Asp Ser Aam Tyr Ile Val Lys Gln Asn Ala Arg 800 805 810 815
Leu Pro Val Lys Trp Met Ala Pro Glu Ser Ile Phe Asp Cys Val Tyr 820 825 830 835
Thr Val Gin Ser Asp Val Trp Ser Tyr Gly Ile Leu Leu Trp Glu Ile 840 845 850 855
Phe Ser Leu Gly Leu Aam Pro Tyr Pro Gly Ile Leu Val Aam Ser Lys 860 865 870
Phe Tyr Lys Leu Val Lys Asp Gly Tyr Gin Met Ala Gin Pro Ala Phe 875 880 885 890
Ala Pro Lys Asn Ile Tyr Ser Ile Met Gin Ala Cys Trp Ala Leu Glu 895 899 900 904
Pro Thr His Arg Pro Thr Phe Gin Gin Ile Cys Ser Phe Leu Gin Glu 905 910 915 920
Gln Ala Gin Glu Asp Arg Arg Arg Tyr Thr Aam Leu Pro Ser 925 930 935 940
Ser Ser Arg Ser Gly Ser Gly Ser Ser Ser Ser Glu Leu Glu 945 950 955 960
Gln Ser Ser Glu His Leu Thr Cys Gin Gin Gly Asp Ile Ala 965 970 975

<210> SEQ ID NO 64
<211> LENGTH: 493
<222> TYPE: PRT
<223> ORGANISM: Artificial
<220> FEATURE: OTHER INFORMATION: human CSF-1R Extracellular Domain
<400> SEQUENCE: 64
Ile Pro Val Ile Glu Pro Ser Val Pro Glu Leu Val Val Lys Pro Gly 1 5 10 15
Ala Thr Val Thr Leu Arg Cys Val Gly Asn Gly Ser Val Glu Trp Asp 20 25 30 35
Gly Pro Asp Pro His Thr Leu Tyr Ser Asp Gly Ser Ser Ser
<table>
<thead>
<tr>
<th></th>
<th>35</th>
<th>40</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ile</td>
<td>Leu</td>
<td>Ser</td>
<td>Thr</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cys</td>
<td>Thr</td>
<td>Glu</td>
<td>Pro</td>
</tr>
<tr>
<td></td>
<td></td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>Tyr</td>
<td>Val</td>
<td>Lys</td>
<td>Asp</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>95</td>
</tr>
<tr>
<td>Val</td>
<td>Val</td>
<td>Phe</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro</td>
<td>Val</td>
<td>Leu</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Met</td>
<td>Arg</td>
<td>His</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>His</td>
<td>Arg</td>
<td>Ala</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Met</td>
<td>Gly</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Lys</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Val</td>
<td>Arg</td>
<td>Ile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Val</td>
<td>Asp</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leu</td>
<td>Ala</td>
<td>Ile</td>
<td>Pro</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Val</td>
<td>Leu</td>
<td>Thr</td>
<td>Leu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyr</td>
<td>Ser</td>
<td>Cys</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phe</td>
<td>Phe</td>
<td>Arg</td>
<td>Val</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asm</td>
<td>Leu</td>
<td>Ile</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Met</td>
<td>Val</td>
<td>Glu</td>
<td>Ala</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td>Pro</td>
<td>Phe</td>
<td>Ser</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Lys</td>
<td>Asp</td>
<td>Thr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lys</td>
<td>Pro</td>
<td>Ser</td>
<td>Glu</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td>Thr</td>
<td>Arg</td>
<td>Ala</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ala</td>
<td>Ala</td>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly</td>
<td>His</td>
<td>Thr</td>
<td>Asp</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Pro</td>
<td>Tyr</td>
<td>Pro</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Val Gln Ser Leu Leu Thr Val Glu Thr Leu Glu His Asn Gln Thr Tyr
450 465 460
Glu Cys Arg Ala His Asn Ser Val Gly Ser Gly Ser Trp Ala Phe Ile
465 470 475 480
Pro Ile Ser Ala Gly Ala His Thr His Pro Pro Asp Glu
485 490

<210> SEQ ID NO 65
<211> LENGTH: 390
<212> TYPE: PROTEIN
<213> ORGANISM: Artificial
<222> FEATURE: OTHER INFORMATION: human CSF-1R fragment del94
<400> SEQUENCE: 65
Ile Pro Val Ile Glu Pro Ser Val Pro Glu Leu Val Val Lys Pro Gly
1 5 10 15
Ala Thr Val Thr Leu Arg Cys Val Gly Asn Gly Ser Val Glu Trp Asp
20 25 30
Gly Pro Pro Ser Pro His Trp Thr Leu Tyr Ser Asp Gly Ser Ser Ser
35 40 45
Ile Leu Ser Thr Asn Asn Ala Thr Phe Gin Asn Thr Gly Thr Tyr Arg
50 55 60
Cys Thr Glu Pro Gly Asp Pro Leu Gly Gly Ser Ala Ala Ile His Leu
65 70 75 80
Tyr Val Lys Asp Pro Ala Arg Pro Trp Asn Val Leu Ala Gin Glu Val
85 90 95
Val Val Phe Glu Asp Gin Asp Ala Leu Leu Pro Cys Leu Leu Thr Asp
100 105 110
Pro Val Leu Glu Ala Gly Val Ser Leu Val Arg Val Arg Gly Arg Pro
115 120 125
Leu Met Arg His Thr Asn Tyr Ser Phe Ser Pro Trp His Gly Phe Thr
130 135 140
Ile His Arg Ala Lys Phe Ile Gin Ser Gin Asp Tyr Gin Cys Ser Ala
145 150 155 160
Leu Met Gly Glu Arg Lys Val Met Ser Ile Ser Ile Arg Leu Lys Val
165 170 175
Gln Lys Val Ile Pro Gly Pro Pro Ala Leu Thr Leu Val Pro Ala Glu
180 185 190
Leu Val Arg Ile Arg Gly Glu Ala Ala Glu Val Cys Ser Ala Ser
195 200 205
Ser Val Asp Val Asn Phe Asp Val Phe Leu Gin His Asn Asn Thr Lys
210 215 220
Leu Ala Ile Pro Gln Gin Ser Gin Val Ser Cys Gin Hist ARG Gin Lys
225 230 235 240
Val Leu Thr Leu Leu Arg Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin Gin G
<table>
<thead>
<tr>
<th>Val</th>
<th>Thr</th>
<th>Trp</th>
<th>Leu</th>
<th>Gln</th>
<th>Cys</th>
<th>Ser</th>
<th>Gly</th>
<th>His</th>
<th>Thr</th>
<th>Asp</th>
<th>Arg</th>
<th>Cys</th>
<th>Asp</th>
<th>Glu</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td>305</td>
<td>310</td>
<td>315</td>
<td>320</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gln</th>
<th>Val</th>
<th>Leu</th>
<th>Gln</th>
<th>Val</th>
<th>Trp</th>
<th>Asp</th>
<th>Asp</th>
<th>Pro</th>
<th>Tyr</th>
<th>Pro</th>
<th>Glu</th>
<th>Val</th>
<th>Leu</th>
<th>Ser</th>
<th>Gln</th>
</tr>
</thead>
<tbody>
<tr>
<td>325</td>
<td>330</td>
<td>335</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glu</th>
<th>Pro</th>
<th>Phe</th>
<th>His</th>
<th>Lys</th>
<th>Val</th>
<th>Thr</th>
<th>Val</th>
<th>Gln</th>
<th>Ser</th>
<th>Leu</th>
<th>Leu</th>
<th>Thr</th>
<th>Val</th>
<th>Glu</th>
<th>Thr</th>
</tr>
</thead>
<tbody>
<tr>
<td>340</td>
<td>345</td>
<td>350</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Glu</th>
<th>His</th>
<th>Asn</th>
<th>Gln</th>
<th>Thr</th>
<th>Tyr</th>
<th>Glu</th>
<th>Cys</th>
<th>Arg</th>
<th>Ala</th>
<th>His</th>
<th>Asn</th>
<th>Ser</th>
<th>Val</th>
<th>Gly</th>
</tr>
</thead>
<tbody>
<tr>
<td>355</td>
<td>360</td>
<td>365</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ser</th>
<th>Gly</th>
<th>Ser</th>
<th>Trp</th>
<th>Ala</th>
<th>Phe</th>
<th>Ile</th>
<th>Pro</th>
<th>Ile</th>
<th>Ser</th>
<th>Ala</th>
<th>Gly</th>
<th>Ala</th>
<th>His</th>
<th>Thr</th>
<th>His</th>
</tr>
</thead>
<tbody>
<tr>
<td>370</td>
<td>375</td>
<td>380</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pro</th>
<th>Pro</th>
<th>Asp</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td>385</td>
<td>386</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**<210> SEQ ID NO 66**

**<211> LENGTH: 292**

**<212> TYPE: PRT**

**<213> ORGANISM: Artificial**

**<220> FEATURE: OTHER INFORMATION: human CSF-1R fragment D1-D3**

**<400> SEQUENCE: 66**

<table>
<thead>
<tr>
<th>Ile</th>
<th>Pro</th>
<th>Val</th>
<th>Ile</th>
<th>Glu</th>
<th>Pro</th>
<th>Ser</th>
<th>Val</th>
<th>Pro</th>
<th>Glu</th>
<th>Leu</th>
<th>Val</th>
<th>Val</th>
<th>Lys</th>
<th>Pro</th>
<th>Gly</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ala</th>
<th>Thr</th>
<th>Val</th>
<th>Thr</th>
<th>Leu</th>
<th>Arg</th>
<th>Cys</th>
<th>Val</th>
<th>Gly</th>
<th>Asn</th>
<th>Gly</th>
<th>Ser</th>
<th>Val</th>
<th>Glu</th>
<th>Trp</th>
<th>Asp</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Pro</th>
<th>Pro</th>
<th>Ser</th>
<th>Pro</th>
<th>His</th>
<th>Trp</th>
<th>Thr</th>
<th>Leu</th>
<th>Tyr</th>
<th>Ser</th>
<th>Asp</th>
<th>Gly</th>
<th>Ser</th>
<th>Ser</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ile</th>
<th>Leu</th>
<th>Ser</th>
<th>Thr</th>
<th>Asn</th>
<th>Asn</th>
<th>Ala</th>
<th>Thr</th>
<th>Phe</th>
<th>Gin</th>
<th>Asn</th>
<th>Thr</th>
<th>Gly</th>
<th>Thr</th>
<th>Tyr</th>
<th>Arg</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cys</th>
<th>Thr</th>
<th>Glu</th>
<th>Pro</th>
<th>Gly</th>
<th>Asp</th>
<th>Pro</th>
<th>Leu</th>
<th>Gly</th>
<th>Gly</th>
<th>Ser</th>
<th>Ala</th>
<th>Ala</th>
<th>Ile</th>
<th>His</th>
<th>Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
<td>80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tyr</th>
<th>Val</th>
<th>Lys</th>
<th>Asp</th>
<th>Pro</th>
<th>Ala</th>
<th>Arg</th>
<th>Pro</th>
<th>Thr</th>
<th>Asp</th>
<th>Val</th>
<th>Ala</th>
<th>Glu</th>
<th>Glu</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>95</td>
<td>95</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Val</th>
<th>Val</th>
<th>Phe</th>
<th>Glu</th>
<th>Asp</th>
<th>Gln</th>
<th>Asp</th>
<th>Ala</th>
<th>Leu</th>
<th>Leu</th>
<th>Pro</th>
<th>Cys</th>
<th>Leu</th>
<th>Leu</th>
<th>Thr</th>
<th>Asp</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>105</td>
<td>110</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pro</th>
<th>Val</th>
<th>Leu</th>
<th>Glu</th>
<th>Ala</th>
<th>Gly</th>
<th>Val</th>
<th>Ser</th>
<th>Leu</th>
<th>Val</th>
<th>Arg</th>
<th>Gly</th>
<th>Arg</th>
<th>Pro</th>
</tr>
</thead>
<tbody>
<tr>
<td>115</td>
<td>120</td>
<td>125</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Met</th>
<th>Arg</th>
<th>His</th>
<th>Thr</th>
<th>Asn</th>
<th>Tyr</th>
<th>Ser</th>
<th>Phe</th>
<th>Ser</th>
<th>Pro</th>
<th>Thr</th>
<th>His</th>
<th>Gly</th>
<th>Phe</th>
<th>Thr</th>
</tr>
</thead>
<tbody>
<tr>
<td>130</td>
<td>135</td>
<td>140</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ile</th>
<th>His</th>
<th>Arg</th>
<th>Ala</th>
<th>Lys</th>
<th>Phe</th>
<th>Ile</th>
<th>Glu</th>
<th>Ser</th>
<th>Gln</th>
<th>Asp</th>
<th>Tyr</th>
<th>Glu</th>
<th>Cys</th>
<th>Ser</th>
<th>Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td>145</td>
<td>150</td>
<td>155</td>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Met</th>
<th>Gly</th>
<th>Glu</th>
<th>Arg</th>
<th>Lys</th>
<th>Val</th>
<th>Met</th>
<th>Ser</th>
<th>Ile</th>
<th>Ser</th>
<th>Ile</th>
<th>Arg</th>
<th>Ala</th>
<th>Leu</th>
<th>Lys</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td>165</td>
<td>170</td>
<td>175</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Glu</th>
<th>Lys</th>
<th>Val</th>
<th>Ile</th>
<th>Pro</th>
<th>Gly</th>
<th>Pro</th>
<th>Pro</th>
<th>Ala</th>
<th>Leu</th>
<th>Thr</th>
<th>Val</th>
<th>Leu</th>
<th>Pro</th>
<th>Ala</th>
<th>Glu</th>
</tr>
</thead>
<tbody>
<tr>
<td>180</td>
<td>185</td>
<td>190</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Val</th>
<th>Arg</th>
<th>Ile</th>
<th>Arg</th>
<th>Gly</th>
<th>Glu</th>
<th>Ala</th>
<th>Glu</th>
<th>Ile</th>
<th>Val</th>
<th>Gly</th>
<th>Ser</th>
<th>Ala</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td>195</td>
<td>200</td>
<td>205</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ser</th>
<th>Val</th>
<th>Asp</th>
<th>Val</th>
<th>Phe</th>
<th>Asp</th>
<th>Val</th>
<th>Phe</th>
<th>Leu</th>
<th>Glu</th>
<th>His</th>
<th>Asn</th>
<th>Asn</th>
<th>Thr</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td>210</td>
<td>215</td>
<td>220</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Leu</th>
<th>Ala</th>
<th>Ile</th>
<th>Pro</th>
<th>Gln</th>
<th>Glu</th>
<th>Ser</th>
<th>Asp</th>
<th>Phe</th>
<th>His</th>
<th>Asn</th>
<th>Asn</th>
<th>Arg</th>
<th>Tyr</th>
<th>Glu</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td>225</td>
<td>230</td>
<td>235</td>
<td>240</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Val</th>
<th>Leu</th>
<th>Thr</th>
<th>Leu</th>
<th>Asn</th>
<th>Leu</th>
<th>Asp</th>
<th>Glu</th>
<th>Val</th>
<th>Asp</th>
<th>Phe</th>
<th>Gln</th>
<th>His</th>
<th>Ala</th>
<th>Gly</th>
<th>Asn</th>
</tr>
</thead>
<tbody>
<tr>
<td>245</td>
<td>250</td>
<td>255</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tyr Ser Cyv Val Ala Ser Val Val Gin Gly Lys His Ser Thr Ser Met
260 265 270
Phe Phe Arg Val Val Glu Ser Ala Tyr Leu Asn Leu Ser Ser Glu Gin
275 280 285
Aam Leu Ile Gin
290

<210> SEQ ID NO 67
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: signal peptide
<400> SEQUENCE: 67
Met Gly Ser Gly Pro Gly Val Leu Leu Leu Leu Val Val Ala Thr Ala
1 5 10 15
Trp His Gly Gin Gly
20

<210> SEQ ID NO 68
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<400> SEQUENCE: 68
cactctcactg ttotcccagt acccccaccagagttta
36

<210> SEQ ID NO 69
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 69
Asp Leu Arg Leu Tyr Phe Arg Val
1 5

<210> SEQ ID NO 70
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 70
Val Ile Trp Ser Gly Gly Gly Thr Asn Tyr Asn Ser Pro Phe Met Ser
1 5 10 15

<210> SEQ ID NO 71
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 71
Gly Phe Ser Leu Thr Ser Tyr Asp Ile Ser
1 5 10

<210> SEQ ID NO 72
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 72
Gly Gln Ser Phe Thr Tyr Pro Thr
1   5

<210> SEQ ID NO 73
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 73
Gly Ser Ser Asn Arg Tyr Thr
1   5

<210> SEQ ID NO 74
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 74
Lys Ala Ser Glu Asp Val Thr Tyr Val Ser
1   5   10

<210> SEQ ID NO 75
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 75
Arg Val Gin Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gin
1   5   10   15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr
20  25  30
Asp Ile Ser Trp Ile Arg Gin Ser Pro Gly Leu Gly Leu Glu Trp Leu
35  40  45
Gly Val Ile Trp Ser Gly Gly Thr Tyr Asn Tyr Asn Pro Phe Met
50  55  60
Ser Arg Leu Arg Ile Ser Lys Asp Ser Ser Arg Ser Gin Val Phe Leu
65  70  75  80
Lys Val Asn Arg Leu Gin Thr Asp Asp Thr Ala Ile Tyr Cys Val
95  100
Arg Asp Leu Arg Leu Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val
105 110
Thr Val Ser Ser
115

<210> SEQ ID NO 76
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 76
Lys Ile Val Met Thr Gin Ser Pro Lys Ser Met Ser Val Ser Val Gly
1   5   10   15
Glu Arg Val Ser Leu Ser Cys Lys Ala Ser Glu Asp Val Gly Thr Tyr
20  25  30
Val Ser Trp Tyr Gin Gin Lys Gin Gin Ser Pro Lys Leu Leu Ile
35  40  45
Tyr Gly Ser Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gin Ala
65 70 75 80
Glu Asp Leu Ala Asp Tyr Ser Cys Gly Gin Ser Phe Thr Tyr Pro Thr
95 90
Phe Gly Thr Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO: 77
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 77
Asp Pro Arg Leu Tyr Phe Asp Val
1 5

<210> SEQ ID NO: 78
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 78
Val Ile Trp Thr Gly Gly Thr Asn Tyr Asn Ser Gly Phe Met Ser
1 5 10 15

<210> SEQ ID NO: 79
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 79
Gly Ser Ser Leu Asp Ser Phe Asp Ile Ser
1 5 10

<210> SEQ ID NO: 80
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 80
Gly Gln Thr Phe Ser Tyr Pro Thr
1 5

<210> SEQ ID NO: 81
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 81
Gly Ala Ser Asn Arg Tyr Thr
1 5

<210> SEQ ID NO: 82
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 82
-continued

Lys Ala Ser Glu Asp Val Val Thr Tyr Val Ser
1 5 10

<210> SEQ ID NO 63
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 83

Gln Val Gin Leu Lys Glu Gly Pro Gly Leu Val Ala Pro Ser Lys
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Ser Ser Leu Asp Ser Phe
20 25 30
Asp Ile Ser Trp Ile Arg Gin Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Gly Phe Met
50 55 60
Ser Arg Leu Arg Ile Ser Lys Asp Asn Ser Lys Ser Gin Val Phe Leu
65 70 75 80
Lys Met Ser Ser Leu Gin Ser Asp Thr Ala Ile Tyr Tyr Cys Val
95 98
Arg Asp Pro Arg Leu Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val
100 105 110
Thr Val Ser Ser
115

<210> SEQ ID NO 84
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Mus musculus

<400> SEQUENCE: 84

Asn Ile Val Met Thr Gin Ser Pro Lys Ser Met Ser Met Ser Val Gly
1 5 10 15
Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asp Val Val Thr Tyr
20 25 30
Val Ser Trp Tyr Gln Gin Ser Pro Gin Ser Pro Lys Leu Leu Ile
35 40 45
Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Ile Gin Ala
65 70 75 80
Glu Asp Leu Ala Asp Tyr Tyr Cys Gly Gin Thr Phe Ser Tyr Pro Thr
85 95 98
Phe Gly Thr Gly Thr Leu Glu Ile Lys
100 105 109

<210> SEQ ID NO 85
<211> LENGTH: 218
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE: OTHER INFORMATION: human CSF-1R fragment domains D4-D5
<400> SEQUENCE: 85

Val Val Glu Ser Ala Tyr Leu Asn Leu Ser Ser Glu Gin Asn Leu Ile
1 5 10 15
-continued

Gln Glu Val Thr Val Gly Glu Gly Leu Asn Leu Lys Val Met Val Glu
20 25 30
Ala Tyr Pro Gly Leu Gin Gly Phe Asn Trp Thr Tyr Leu Gly Pro Phe
35 40 45
Ser Asp His Gin Pro Glu Pro Lys Leu Ala Asn Ala Thr Thr Lys Asp
50 55 60
Thr Tyr Arg His Thr Phe Thr Leu Ser Leu Pro Arg Leu Lys Pro Ser
65 70 75 80
Glu Ala Gly Arg Tyr Ser Phe Leu Ala Arg Asn Pro Gly Gly Gly Trp Arg
85 90 95
Ala Leu Thr Phe Glu Leu Thr Arg Tyr Pro Pro Glu Val Ser Val
100 105 110
Ile Trp Thr Phe Ile Asn Gly Ser Gly Thr Leu Leu Cys Ala Ala Ser
115 120 125
Gly Tyr Pro Gin Pro Asn Val Thr Trp Leu Gin Cys Ser Gly His Thr
130 135 140
Asp Arg Cys Asp Glu Ala Gin Val Leu Gin Val Trp Asp Asp Pro Tyr
145 150 155 160
Pro Glu Val Leu Ser Gin Glu Pro Phe His Lys Val Thr Val Gin Ser
165 170 175
Leu Leu Thr Val Thr Leu Glu His Asn Gin Thr Tyr Gly Cys Arg
180 185 190
Ala His Asn Ser Val Gly Ser Tyr Ser Thr Ala Phe Ile Pro Ile Ser
195 200 205
Ala Gly Ala His Thr His Pro Pro Asp Glu
210 215

<210> SEQ ID NO: 86
<211> LENGTH: 554
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 86
Met Thr Ala Pro Gly Ala Ala Gly Arg Cys Pro Pro Thr Thr Trp Leu
1  5 10 15
Gly Ser Leu Leu Leu Leu Val Cys Leu Ala Ser Arg Ser Ile Thr
20 25 30
Glu Glu Val Ser Glu Tyr Cys Ser His Met Ile Gly Ser Gly His Leu
35 40 45
Gln Ser Leu Gin Arg Leu Ile Asp Ser Gin Met Glu Thr Ser Cys Gin
50 55 60
Ile Thr Phe Glu Phe Val Asp Gin Glu Gin Leu Lys Asp Pro Val Cys
65 70 75 80
Tyr Leu Lys Lys Ala Phe Leu Leu Val Gin Asp Ile Met Glu Asp Thr
85 90 95
Met Arg Phe Arg Asp Asp Thr Pro Arg Asn Ala Ile Ala Ile Val Gin Leu
100 105 110
Gln Glu Leu Ser Leu Arg Leu Lys Ser Cys Phe Thr Lys Asp Tyr Glu
115 120 125
Glu His Asp Lys Ala Cys Val Arg Thr Phe Tyr Glu Thr Pro Leu Gin
130 135 140
Leu Leu Glu Lys Val Lys Asn Val Phe Asn Glu Thr Lys Asn Leu Leu

<210> SEQ ID NO 87
<211> LENGTH: 242
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 87

Met Pro Arg Gly Phe Thr Trp Leu Arg Tyr Leu Gly Ile Phe Leu Gly
Val Ala Leu Gly Asn Glu Pro Leu Glu Met Trp Pro Leu Thr Glu Asn
Glu Glu Cys Thr Val Thr Gly Phe Leu Arg Asp Lys Leu Glu Tyr Arg
Ser Arg Leu Gin Tyr Met Lys His Tyr Phe Pro Ile Asn Tyr Lys Ile
Ser Val Pro Tyr Glu Gly Val Phe Arg Ile Ala Asn Val Thr Arg Leu
Gln Arg Ala Gin Val Ser Glu Arg Leu Arg Tyr Leu Trp Val Leu
Val Ser Leu Ser Ala Thr Glu Ser Val Gin Asp Val Leu Leu Glu Gly
His Pro Ser Thr Lys Tyr Leu Gln Val Glu Val Thr Leu Leu Leu Leu
Val Gin Gin Gly Leu Thr Asp Val Glu Val Ser Pro Lys Val Glu Ser
Val Leu Ser Leu Leu Asn Ala Pro Gly Pro Asn Leu Lys Leu Val Arg
Pro Lys Ala Leu Leu Asp Asn Cys Phe Arg Val Met Glu Leu Leu Tyr
Cys Ser Cys Cys Lys Gin Ser Ser Val Leu Asn Thr Val Gin Asp Cys Glu
Val Pro Ser Pro Gin Ser Cys Ser Pro Glu Pro Ser Leu Gin Tyr Ala
Val Pro Ser Pro Gin Ser Cys Ser Pro Glu Pro Ser Leu Gin Tyr Ala
His Ser Thr Gly Ser Val Arg Pro Val Arg Ala Gin Gly Gly Glu Gly Leu
Leu Pro

<210> SEQ ID NO 88
<211> LENGTH: 290
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 88

Met Arg Ile Phe Ala Val Phe Ile Phe Met Thr Tyr Trp His Leu Leu
Asn Ala Phe Thr Val Thr Val Pro Lys Asp Leu Tyr Val Val Glu Tyr
Gly Ser Asn Met Thr Ile Glu Cys Lys Phe Pro Val Glu Lys Gin Leu
Asp Leu Ala Ala Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile
### -continued

<table>
<thead>
<tr>
<th>Ile</th>
<th>Gln</th>
<th>Phe</th>
<th>Val</th>
<th>His</th>
<th>Gly</th>
<th>Glu</th>
<th>Glu</th>
<th>Asp</th>
<th>Leu</th>
<th>Val</th>
<th>Gln</th>
<th>His</th>
<th>Ser</th>
<th>Ser</th>
<th>65</th>
<th>70</th>
<th>75</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tyr</td>
<td>Arg</td>
<td>Gln</td>
<td>Arg</td>
<td>Ala</td>
<td>Arg</td>
<td>Leu</td>
<td>Leu</td>
<td>Lys</td>
<td>Asp</td>
<td>Gln</td>
<td>Leu</td>
<td>Ser</td>
<td>Leu</td>
<td>Gly</td>
<td>Asn</td>
<td>85</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Ala</td>
<td>Ala</td>
<td>Leu</td>
<td>Gln</td>
<td>Ile</td>
<td>Thr</td>
<td>Asp</td>
<td>Val</td>
<td>Leu</td>
<td>Gln</td>
<td>Asp</td>
<td>Ala</td>
<td>Gly</td>
<td>Val</td>
<td>Tyr</td>
<td>100</td>
<td>105</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Arg</td>
<td>Cys</td>
<td>Met</td>
<td>Ile</td>
<td>Ser</td>
<td>Tyr</td>
<td>Gly</td>
<td>Ala</td>
<td>Asp</td>
<td>Tyr</td>
<td>Lys</td>
<td>Arg</td>
<td>Ile</td>
<td>Thr</td>
<td>Val</td>
<td>115</td>
<td>120</td>
<td>125</td>
<td></td>
</tr>
<tr>
<td>Lys</td>
<td>Val</td>
<td>Aem</td>
<td>Ala</td>
<td>Pro</td>
<td>Tyr</td>
<td>Aem</td>
<td>Lys</td>
<td>Ile</td>
<td>Aem</td>
<td>Gln</td>
<td>Arg</td>
<td>Ile</td>
<td>Leu</td>
<td>Val</td>
<td>130</td>
<td>135</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Asp</td>
<td>Pro</td>
<td>Val</td>
<td>Thr</td>
<td>Ser</td>
<td>Glu</td>
<td>His</td>
<td>Leu</td>
<td>Thr</td>
<td>Cys</td>
<td>Gln</td>
<td>Ala</td>
<td>Gly</td>
<td>Tyr</td>
<td></td>
<td>145</td>
<td>150</td>
<td>155</td>
<td>160</td>
</tr>
<tr>
<td>Pro</td>
<td>Lys</td>
<td>Ala</td>
<td>Gln</td>
<td>Val</td>
<td>Ile</td>
<td>Trp</td>
<td>Thr</td>
<td>Ser</td>
<td>Ser</td>
<td>Asp</td>
<td>His</td>
<td>Gln</td>
<td>Val</td>
<td>Leu</td>
<td>Ser</td>
<td>165</td>
<td>170</td>
<td>175</td>
</tr>
<tr>
<td>Gly</td>
<td>Lys</td>
<td>Thr</td>
<td>Thr</td>
<td>Thr</td>
<td>Thr</td>
<td>Aem</td>
<td>Ser</td>
<td>Lys</td>
<td>Arg</td>
<td>Gln</td>
<td>Glu</td>
<td>Lys</td>
<td>Leu</td>
<td>Phe</td>
<td>Asn</td>
<td></td>
<td>180</td>
<td>185</td>
</tr>
<tr>
<td>Val</td>
<td>Thr</td>
<td>Ser</td>
<td>Thr</td>
<td>Leu</td>
<td>Arg</td>
<td>Ile</td>
<td>Aem</td>
<td>Thr</td>
<td>Thr</td>
<td>Aem</td>
<td>Gln</td>
<td>Ile</td>
<td>Phe</td>
<td>Tyr</td>
<td></td>
<td></td>
<td>195</td>
<td>200</td>
</tr>
<tr>
<td>Cys</td>
<td>Thr</td>
<td>Phe</td>
<td>Arg</td>
<td>Arg</td>
<td>Leu</td>
<td>Asp</td>
<td>Pro</td>
<td>Glu</td>
<td>Asn</td>
<td>His</td>
<td>Thr</td>
<td>Ala</td>
<td>Glu</td>
<td>Leu</td>
<td></td>
<td>210</td>
<td>215</td>
<td>220</td>
</tr>
<tr>
<td>Val</td>
<td>Ile</td>
<td>Pro</td>
<td>Glu</td>
<td>Leu</td>
<td>Pro</td>
<td>Leu</td>
<td>Ala</td>
<td>His</td>
<td>Pro</td>
<td>Pro</td>
<td>Asn</td>
<td>Glu</td>
<td>Arg</td>
<td>Thr</td>
<td>His</td>
<td></td>
<td>225</td>
<td>230</td>
</tr>
<tr>
<td>Leu</td>
<td>Val</td>
<td>Ile</td>
<td>Leu</td>
<td>Gly</td>
<td>Ala</td>
<td>Leu</td>
<td>Leu</td>
<td>Cys</td>
<td>Leu</td>
<td>Gly</td>
<td>Val</td>
<td>Ala</td>
<td>Leu</td>
<td>Thr</td>
<td></td>
<td></td>
<td>245</td>
<td>250</td>
</tr>
<tr>
<td>Phe</td>
<td>Ile</td>
<td>Phe</td>
<td>Arg</td>
<td>Leu</td>
<td>Arg</td>
<td>Lys</td>
<td>Gly</td>
<td>Arg</td>
<td>Met</td>
<td>Met</td>
<td>Asp</td>
<td>Val</td>
<td>Lys</td>
<td>Lys</td>
<td>Cys</td>
<td></td>
<td>260</td>
<td>265</td>
</tr>
<tr>
<td>Gly</td>
<td>Ile</td>
<td>Gln</td>
<td>Asp</td>
<td>Thr</td>
<td>Aem</td>
<td>Ser</td>
<td>Lys</td>
<td>Gln</td>
<td>Ser</td>
<td>Asp</td>
<td>Thr</td>
<td>His</td>
<td>Leu</td>
<td>Glu</td>
<td></td>
<td></td>
<td>275</td>
<td>280</td>
</tr>
<tr>
<td>Glu</td>
<td>Thr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>290</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**<210> SEQ ID NO 99**
**<211> LENGTH: 118**
**<212> TYPE: PRT**
**<213> ORGANISM: Artificial sequence**
**<220> FEATURE:**
**<223> OTHER INFORMATION: sequence is synthesized**

**<400> SEQUENCE: 89**

| Glu  | Val  | Gln  | Leu  | Val  | Val  | Gln  | Ser  | Gly  | Gly  | Gly  | Leu  | Val  | Gln  | Pro  | Gly  | Gly  | 1    | 5    | 10   | 15   |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Ser  | Leu  | Arg  | Leu  | Ser  | Cys  | Ala  | Ala  | Ser  | Gly  | Phe  | Thr  | Phe  | Ser  | Asp  | Ser  | 20   | 25   | 30   |      |
| Trp  | Ile  | His  | Trp  | Val  | Arg  | Gln  | Ala  | Pro  | Gly  | Lys  | Gly  | Leu  | Gln  | Trp  | Val  | 35   | 40   | 45   |      |
| Ala  | Trp  | Ile  | Ser  | Pro  | Tyr  | Gly  | Gly  | Ser  | Thr  | Tyr  | Tyr  | Ala  | Asp  | Ser  | Val  | 50   | 55   | 60   |      |
| Lys  | Gly  | Arg  | Phe  | Thr  | Ile  | Ser  | Ala  | Ser  | Ala  | Asp  | Thr  | Ser  | Lys  | Aem  | Thr  | Ala  | 65   | 70   | 75   | 80   |
| Leu  | Gln  | Met  | Aem  | Ser  | Leu  | Arg  | Ala  | Gln  | Ser  | Ala  | Val  | Tyr  | Tyr  | Cys  | 85   | 90   | 95   |      |
| Ala  | Arg  | Arg  | His  | Thr  | Pro  | Gly  | Gly  | Phe  | Asp  | Tyr  | Trp  | Gly  | Gln  | Gly  | Thr  | 100  | 105  | 110  |      |
Leu Val Thr Val Ser Ala  
115

<210> SEQ ID NO 90
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 90

Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly  
1  5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ser  
20 25 30
Trp Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Gin Trp Val  
35 40 45
Ala Trp Ile Ser Pro Tyr Gly Gly Ser Thr Tyr Ala Asp Ser Val  
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr  
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95
Ala Arg Arg His Trp Pro Gly Phe Asp Tyr Trp Gly Gin Gly Thr  
100 105 110
Leu Val Thr Val Ser Ala  
115

<210> SEQ ID NO 91
<211> LENGTH: 118
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 91

Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly Gly  
1  5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Ser  
20 25 30
Trp Ile His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Gin Trp Val  
35 40 45
Ala Trp Ile Leu Pro Tyr Gly Gly Ser Ser Tyr Tyr Ala Asp Ser Val  
50 55 60
Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr  
65 70 75 80
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95
Ala Arg Arg His Trp Pro Gly Phe Asp Tyr Trp Gly Gin Gly Thr  
100 105 110
Leu Val Thr Val Ser Ala  
115

<210> SEQ ID NO 92
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: sequence is synthesized

SEQUENCE: 92

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg
100 105

SEQ ID NO: 93
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial sequence
OTHER INFORMATION: sequence is synthesized

SEQUENCE: 93

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Leu Tyr His Pro Ala
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg
100 105

SEQ ID NO: 94
LENGTH: 108
TYPE: PRT
ORGANISM: Artificial sequence
OTHER INFORMATION: sequence is synthesized

SEQUENCE: 94

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
-continued

Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Tyr Ala Pro Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> SEQ ID NO 95
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 95

Amp Ile Gin Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1  5 10 15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Val Ser Thr Ala
20 25 30
Val Ala Trp Tyr Gin Gin Lys Pro Gin Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Tyr Thr Val Pro Trp
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> SEQ ID NO 96
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 96

Amp Ile Gin Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1  5 10 15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Val Ile Gin Thr Phe
20 25 30
Leu Ala Trp Tyr Gin Gin Lys Pro Gin Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Thr Leu Ala Ser Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Tyr Thr Val Pro Arg
85 90 95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> SEQ ID NO 97
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 98

Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1  5  10  15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Val Ser Thr Ala

20  25  30
Val Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly

50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro

65  70  75  80
Glu Asp Phe Ala Thr Tyr Cys Gin Gin Gly Tyr Gly Val Pro Arg

85  90  95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg

100 105

<210> SEQ ID NO 99
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 108

Asp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly

1  5  10  15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Val Ser Thr Ala

20  25  30
Val Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile

35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly

50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro

65  70  75  80
Glu Asp Phe Ala Thr Tyr Cys Gin Gin Gly Tyr Gly Val Pro Arg

85  90  95
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg

100 105 105
<table>
<thead>
<tr>
<th>1</th>
<th>Val Ala Trp Tyr Glu Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>40</td>
</tr>
<tr>
<td>50</td>
<td>Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly</td>
</tr>
<tr>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro</td>
</tr>
<tr>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td>Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Phe Ile Thr Pro Thr</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
</tr>
<tr>
<td>95</td>
<td>Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg</td>
</tr>
<tr>
<td>100</td>
<td>105</td>
</tr>
</tbody>
</table>

-continued
<210> SEQ ID NO 102
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 102

Amp Ile Gin Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1  5  10  15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Val Ser Thr Ala  20  25  30
Val Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Gly Leu Leu Ile  35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly  50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro  65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Leu Phe Thr Pro Pro  95  90
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg 100 105

<210> SEQ ID NO 103
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 103

Amp Ile Gin Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1  5  10  15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gin Asp Val Ser Thr Ala  20  25  30
Val Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Gly Leu Leu Ile  35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly  50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro  65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Ser Leu Phe Thr Pro Pro  95  90
Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys Arg 100 105

<210> SEQ ID NO 104
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 104

Amp Ile Gin Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1  5  10  15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Amp Val Ser Thr Ala
20  25  30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gln Val Pro Ser Arg Phe Ser Gly
50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Trp Tyr His Pro Pro
85  90  95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> SEQ ID NO 105
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 105
Amp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1  5  10  15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Amp Val Ser Thr Ala
20  25  30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gln Val Pro Ser Arg Phe Ser Gly
50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Phe Tyr Ile Pro Pro
85  90  95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> SEQ ID NO 106
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: sequence is synthesized

<400> SEQUENCE: 106
Amp Ile Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1  5  10  15
Amp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Amp Val Ser Thr Ala
20  25  30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35  40  45
Tyr Ser Ala Ser Phe Leu Tyr Ser Gln Val Pro Ser Arg Phe Ser Gly
50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Phe Tyr Ile Pro Pro
85  90  95
1. An antibody which binds to human CSF-1R wherein the antibody is administered in combination with an antibody which binds to human PD-L1 for use in the treatment of cancer, for use in the prevention or treatment of metastasis, for use in the treatment inflammatory diseases, for use in the treatment of bone loss, for use in treating or delaying progression of an immune related disease such as tumor immunity, or for use in stimulating an immune response or function, such as T cell activity,

wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or
b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or
c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or
d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or
e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56, and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:92, or
b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or
c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or
d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or
e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or
f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or
g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or
l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
p) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:107.

2. The antibody according to claim 1, for use in the treatment of cancer.

3. The antibody according to claim 2, for use in the treatment of breast cancer, lung cancer, colon cancer, ovarian cancer, melanoma cancer, bladder cancer, renal cancer, kidney cancer, liver cancer, head and neck cancer, colorectal cancer, or other cancer.
cancer, pancreatic cancer, gastric carcinoma, cancer, esophageal cancer, mesothelioma, prostate cancer, leukemia, lymphomas, myelomas.

4. The antibody according to claim 1, for use in the prevention or treatment of metastasis.

5. The antibody according to claim 1, for use in the treatment of bone loss.

6. The antibody according to claim 1, for use in the treatment of inflammatory diseases.

7. The antibody according to claim 1, for use in treating or delaying progression of an immune related disease such as tumor immunity.

8. The antibody according to claim 1, for use in stimulating an immune function, such as T cell activity.

9. An antibody which binds to human CSF-1R wherein the antibody is administered in combination with an antibody which binds to human PD-L1, for use in

i) the inhibition of cell proliferation in CSF-1R ligand-dependent and/or CSF-1 ligand-independent CSF-1R expressing tumor cells;

ii) the inhibition of cell proliferation of tumors with CSF-1 R ligand-dependent and/or CSF-1 R ligand-independent CSF-1R expressing macrophage infiltrate;

iii) the inhibition of cell survival (in CSF-1 R ligand-dependent and/or CSF-1 R ligand-independent) CSF-1R expressing monocytes and macrophages; and/or

iv) the inhibition of cell differentiation (in CSF-1 R ligand-dependent and/or CSF-1 R ligand-independent) CSF-1R expressing monocytes into macrophages, wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

10. An antibody which binds to human CSF-1R, for use in the treatment of a patient having a CSF-1R expressing tumor or having a tumor with CSF-1R expressing macrophage infiltrate, wherein the tumor is characterized by an increase of CSF-1R ligand and wherein the anti-CSF-1R antibody is administered in combination with an antibody which binds to human PD-L1, wherein the antibody which binds to human CSF-1R used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:23 and a light chain variable domain VL of SEQ ID NO:24, or

b) a heavy chain variable domain VH of SEQ ID NO:31 and a light chain variable domain VL of SEQ ID NO:32, or

c) a heavy chain variable domain VH of SEQ ID NO:39 and a light chain variable domain VL of SEQ ID NO:40, or

d) a heavy chain variable domain VH of SEQ ID NO:47 and a light chain variable domain VL of SEQ ID NO:48, or

e) a heavy chain variable domain VH of SEQ ID NO:55 and a light chain variable domain VL of SEQ ID NO:56;

and the antibody which binds to human PD-L1 used in the combination therapy is characterized in comprising

a) a heavy chain variable domain VH of SEQ ID NO:89 and a light chain variable domain VL of SEQ ID NO:92, or

b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or

c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or

d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or

e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or

f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or

g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or

h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or

i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or

j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or

k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

l) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or

m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or

n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or

o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or

p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.
b) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:93, or
c) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:94, or
d) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:95, or
e) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:96, or
f) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:97, or
g) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:98, or
h) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:99, or
i) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:100, or
j) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:101, or
k) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:102, or

1) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:103, or
m) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:104, or
n) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:105, or
o) a heavy chain variable domain VH of SEQ ID NO:90 and a light chain variable domain VL of SEQ ID NO:106, or
p) a heavy chain variable domain VH of SEQ ID NO:91 and a light chain variable domain VL of SEQ ID NO:107.

11. The antibody according to any one of the preceding claims, characterized in that said antibodies are of human IgG1 subclass or human IgG4 subclass.

12. The antibody according to any one of the preceding claims, characterized in that said antibodies have reduced or minimal effector function.

13. The antibody according to any one of the preceding claims, characterized in that the minimal effector function results from an effectorless Fc mutation.

14. The antibody according to any one of the preceding claims, characterized in that the effectorless Fc mutation is L234A/L235A or L234A/L235A/P329G or N297A or D265A/N297A.

* * * * *